

## Health Technology Assessment

Volume 24 • Issue 56 • November 2020

ISSN 1366-5278

# An interactive website to aid young women's choice of contraception: feasibility and efficacy RCT

*Judith Stephenson, Julia V Bailey, Ann Blandford, Nataliya Brima, Andrew Copas, Preethy D'Souza, Anasztazia Gubijev, Rachael Hunter, Jill Shawe, Greta Rait and Sandy Oliver*





# An interactive website to aid young women's choice of contraception: feasibility and efficacy RCT

Judith Stephenson<sup>1,\*</sup> Julia V Bailey<sup>2</sup> Ann Blandford<sup>3</sup>  
Nataliya Brima<sup>4</sup> Andrew Copas<sup>4</sup> Preethy D'Souza<sup>5</sup>  
Anasztazia Gubijev<sup>1</sup> Rachael Hunter<sup>6</sup> Jill Shawe<sup>7</sup>  
Greta Rait<sup>8</sup> and Sandy Oliver<sup>5,9</sup>

<sup>1</sup>UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK

<sup>2</sup>Department of Primary Care and Population Health, University College London, Royal Free Hospital, London, UK

<sup>3</sup>UCL Interaction Centre (UCLIC), University College London, London, UK

<sup>4</sup>Institute for Global Health, University College London, London, UK

<sup>5</sup>Department of Social Science, UCL Institute of Education, University College London, London, UK

<sup>6</sup>Health Economics, University College London, London, UK

<sup>7</sup>Institute of Health and Community, University of Plymouth, Plymouth, UK

<sup>8</sup>PRIMENT Clinical Trials Unit, Department of Primary Care and Population Health, University College London, Royal Free Hospital, London, UK

<sup>9</sup>Africa Centre for Evidence, Faculty of Humanities, University of Johannesburg, Johannesburg, South Africa

\*Corresponding author

**Declared competing interests of authors:** none.

Published November 2020

DOI: 10.3310/hta24560

This report should be referenced as follows:

Stephenson J, Bailey JV, Blandford A, Brima N, Copas A, D'Souza P, *et al.* An interactive website to aid young women's choice of contraception: feasibility and efficacy RCT. *Health Technol Assess* 2020;**24**(56).

*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.



ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 3.370

*Health Technology Assessment* is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

The full HTA archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/hta](http://www.journalslibrary.nihr.ac.uk/hta). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

## This report

The research reported in this issue of the journal was funded by the HTA programme as project number 13/79/09. The contractual start date was in October 2015. The draft report began editorial review in February 2019 and was accepted for publication in November 2019. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2020. This work was produced by Stephenson *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).

## Editor-in-Chief of *Health Technology Assessment* and NIHR Journals Library

---

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

### NIHR Journals Library Editors

---

**Professor John Powell** Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson** Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont** Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid** Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie** Chair in Medical Statistics, University of Edinburgh, UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood** Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

# Abstract

## An interactive website to aid young women's choice of contraception: feasibility and efficacy RCT

Judith Stephenson<sup>1,\*</sup> Julia V Bailey<sup>2</sup> Ann Blandford<sup>3</sup> Nataliya Brima<sup>4</sup>  
Andrew Copas<sup>4</sup> Preethy D'Souza<sup>5</sup> Anasztazia Gubijev<sup>1</sup>  
Rachael Hunter<sup>6</sup> Jill Shawe<sup>7</sup> Greta Rait<sup>8</sup> and Sandy Oliver<sup>5,9</sup>

<sup>1</sup>UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK

<sup>2</sup>Department of Primary Care and Population Health, University College London, Royal Free Hospital, London, UK

<sup>3</sup>UCL Interaction Centre (UCLIC), University College London, London, UK

<sup>4</sup>Institute for Global Health, University College London, London, UK

<sup>5</sup>Department of Social Science, UCL Institute of Education, University College London, London, UK

<sup>6</sup>Health Economics, University College London, London, UK

<sup>7</sup>Institute of Health and Community, University of Plymouth, Plymouth, UK

<sup>8</sup>PRIMENT Clinical Trials Unit, Department of Primary Care and Population Health, University College London, Royal Free Hospital, London, UK

<sup>9</sup>Africa Centre for Evidence, Faculty of Humanities, University of Johannesburg, Johannesburg, South Africa

\*Corresponding author [Judith.stephenson@ucl.ac.uk](mailto:Judith.stephenson@ucl.ac.uk)

**Background:** Effective use of contraception can reduce numbers of unintended pregnancies, but misunderstandings and concerns about contraception abound. Increasingly, women seek health-care information online.

**Objectives:** To develop an interactive website to aid informed choice of contraceptive method, including long-acting reversible contraception (Phase I), and test its effectiveness in a parallel, single-blind randomised trial (Phase II). Approval came from London – Camden & King's Cross Research Ethics Committee (reference 17/LO/0112).

**Setting and participants:** For both phases, women aged 15–30 years were recruited from general practice, sexual health services, maternity services, community pharmacies and an abortion service.

**Design:** In Phase I, we conducted three systematic literature reviews, a review of YouTube (YouTube, LLC, San Bruno, CA, USA) videos about contraception, and focus groups and interviews with young women to explore barriers to and concerns and misperceptions about contraception. We then iteratively co-designed an interactive website, Contraception Choices [URL: [www.contraceptionchoices.org](http://www.contraceptionchoices.org) (accessed June 2020)], with young women and a software company. In Phase II, we evaluated the website through a randomised trial that began as a feasibility trial. Early demand for Contraception Choices stimulated a design change from a feasibility to an efficacy trial, with follow-up for clinical outcomes at 3 and 6 months. A randomisation list was incorporated into the trial software program to allocate participants to the intervention (website) or control group (standard care).

**Intervention:** Contraception Choices is a co-designed, evidence-based, interactive website to aid informed choice of contraception. It provides information about different methods, addresses common concerns and offers tailored contraceptive options in response to individual preferences.

**Main outcome measures:** Qualitative – participant views and experience of the intervention, assessed through qualitative interviews. Quantitative primary outcomes – follow-up rate at 6 months in the initial feasibility trial, using a long-acting reversible contraception method, and satisfaction with contraceptive method at 6 months in the efficacy trial.

**Results:** A total of 927 women were randomised online to the website ( $n = 464$ ) or control group ( $n = 463$ ), of whom 739 (80%) provided follow-up data at 6 months [786 women (85%) provided data at 3 and/or 6 months that were included in the analysis of primary outcomes]. There was little difference between groups in the proportion using long-acting reversible contraception at 6 months [30.4% intervention vs. 31.0% control, adjusted odds ratio after imputation 0.87 (95% confidence interval 0.60 to 1.27)] or in satisfaction with contraceptive method [proportion being 'satisfied' or 'very satisfied', 82.6% intervention vs. 82.1% control, adjusted odds ratio 0.93 (95% confidence interval 0.69 to 1.25)]. Qualitative evaluation indicated highly positive views about the website and increased knowledge of contraceptive methods that could dispel misperceptions. Women appreciated having information tailored to their specific needs and felt better prepared before consultations.

**Limitations:** We did not include intermediate measures, such as knowledge of contraceptive methods, intention to change method or confidence in discussing contraception with a health-care professional, which may have indicated other benefits of using the website. In future, the website should be studied in different settings (e.g. schools and in routine practice) to see whether or not it improves the quality or efficiency of contraceptive consultations.

**Conclusions:** Our systematic review indicated wide-ranging influences on women's use of contraception globally. The website, Contraception Choices, was very popular with young women and contraception service providers. It was not associated with statistically significant differences in use of long-acting reversible contraception or satisfaction with contraceptive method at 6 months.

**Trial registration:** Current Controlled Trials ISRCTN13247829.

**Funding:** This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 24, No. 56. See the NIHR Journals Library website for further project information.



# Contents

List of tables	ix
List of figures	xi
List of abbreviations	xiii
Plain English summary	xv
Scientific summary	xvii
<b>Chapter 1</b> Background	<b>1</b>
Study aims and objectives	2
<i>Phase I objectives</i>	2
<i>Phase II objectives (including transition from a feasibility trial to an efficacy trial)</i>	2
Study setting	3
<b>Chapter 2</b> Phase I: design and development of the website	<b>5</b>
Overview of methods	5
Objective 1 (systematic reviews)	5
<i>Systematic review 1: factors influencing contraception choice, uptake and use – a meta-synthesis of systematic reviews</i>	5
<i>Systematic review 2: effectiveness of interactive digital interventions for contraception choice, uptake and use</i>	5
<i>Systematic review 3: effectiveness of face-to-face interventions for contraception and review of theoretical approaches to contraception decision-making</i>	6
Objective 2 (views of contraceptive service users and providers)	6
<i>Recruitment</i>	6
<i>Topic guide</i>	7
<i>Analysis of qualitative data</i>	7
<i>Key findings</i>	7
<i>Views of health-care providers</i>	7
<i>Objective 2 (review of YouTube videos)</i>	7
Objective 3 (applying the information from objectives 1 and 2 to identify the key design issues and content for an interactive website)	8
<i>Website aims</i>	8
<i>Guiding principles underpinning the Contraception Choices website</i>	8
<i>Understanding the context and complexity of contraceptive decision-making</i>	8
Objective 4 (co-developing the website with young women and professionals)	10
<i>Expert (health professional) intervention content workshop</i>	10
<i>Clinical content of the website</i>	11
<i>Website development process</i>	11
<i>Information on contraceptive methods</i>	11
<i>Interactive tailored decision aid</i>	12
<i>Further information section</i>	12
<i>Additional evaluation of Contraception Choices</i>	12

## CONTENTS

<b>Chapter 3</b> Phase II: evaluation trial of the website	<b>15</b>
Methods	15
<i>Original feasibility trial design (objectives 5 and 6)</i>	15
<i>Setting</i>	15
<i>Inclusion criteria</i>	15
<i>Exclusion criteria</i>	15
The intervention	15
Outcome measures	16
<i>Primary outcome</i>	16
<i>Secondary outcomes: quantitative</i>	16
<i>Secondary outcomes: qualitative</i>	16
Sample size	17
Baseline survey	17
Follow-up surveys	17
Procedures: recruitment in clinics	17
Randomisation procedures	18
Follow-up procedures	18
Study timeline	19
Trial process evaluation	20
<i>Aim</i>	20
<i>Methods (trial procedures, rapid follow-up, then interviews)</i>	20
<i>Findings</i>	20
<i>Conclusions for the trial</i>	20
Transition from feasibility to efficacy trial (modified objective 7)	21
Statistical analysis	21
Costs of contraception and budget impact analysis	22
Ethics issues	23
<b>Chapter 4</b> Trial results	<b>25</b>
Recruitment	25
Follow-up	25
Qualitative findings	25
<i>Information/website content</i>	25
<i>Design and format</i>	27
<i>Health professional interaction</i>	27
<i>Reported impacts of the Contraception Choices website</i>	27
<i>Health service barriers to accessing contraception</i>	28
<i>Being part of the study</i>	28
Quantitative findings	28
<i>Primary outcomes</i>	30
<i>Secondary outcomes</i>	31
Budget impact analysis	32
Health-related quality of life	33
<b>Chapter 5</b> Discussion	<b>35</b>
<b>Chapter 6</b> Conclusions/recommendations	<b>37</b>
<b>Acknowledgements</b>	<b>39</b>
<b>References</b>	<b>41</b>

# List of tables

<b>TABLE 1</b>	Rationale for Contraception Choices website content	<b>12</b>
<b>TABLE 2</b>	Study sites	<b>15</b>
<b>TABLE 3</b>	Cost of contraception-related resource use	<b>23</b>
<b>TABLE 4</b>	Baseline characteristics by study arm	<b>28</b>
<b>TABLE 5</b>	Comparison of outcomes between study arms	<b>30</b>
<b>TABLE 6</b>	Post hoc per-protocol analysis of primary outcomes	<b>32</b>
<b>TABLE 7</b>	Budget impact assessment reporting average cost per woman over 6 months	<b>33</b>
<b>TABLE 8</b>	Average cost per woman (excluding pregnancy) and cost difference between Contraception Choices and control by recruiting site	<b>33</b>



# List of figures

<b>FIGURE 1</b> Follow-up procedures in feasibility trial	<b>19</b>
<b>FIGURE 2</b> Consolidated Standards of Reporting Trials (CONSORT) flow diagram	<b>26</b>



## List of abbreviations

BPAS	British Pregnancy Advisory Service	NICE	National Institute for Health and Care Excellence
CI	confidence interval	OR	odds ratio
GP	general practitioner	PSSRU	Personal Social Services Research Unit
IDI	interactive digital intervention	QALY	quality-adjusted life-year
LARC	long-acting reversible contraception	RCT	randomised controlled trial
MPC	Margaret Pyke Centre	SE	standard error
MSc	Master of Science		





# Plain English summary

## What was the question?

Choosing between types of contraception can be challenging, so can a website help women make the right choice for them?

## What did we do?

We asked women what they think about contraception. We looked at other studies and YouTube (YouTube, LLC, San Bruno, CA, USA) videos. We then designed the Contraception Choices website with young women [URL: [www.contraceptionchoices.org](http://www.contraceptionchoices.org) (accessed January 2020)].

The website describes each type of contraception and compares them side by side. When users answer questions about what matters to them, the website suggests three types of contraception they might like. A total of 927 women helped us test the website in an online trial. We asked everyone what contraception they were using and how satisfied they were with it 6 months later.

## What did we find?

Women really liked the website. Ninety-seven per cent of participants found it helpful or very helpful for 'getting useful information about contraception' and 87% responded that it was helpful or very helpful for 'finding a method of contraception that is right for you'. Comments included:

*I feel very well educated thanks to the website – I wish someone had explained about all the different choices years ago.*

*It's cleared up some of my doubts and things I worried about (probably unconsciously!) about hormonal contraception.*

However, seeing the website did not mean that women used a more reliable type of contraception. Women were just as satisfied with their contraception whether or not they had seen the website. We think that this is because many other factors are involved; for example, some women found it difficult to access long-acting contraception methods from health services.

## What does this mean?

Young women liked the Contraception Choices website and found it useful. Women can be put off by contraception side effects and the views of partners, friends, family and others. On its own, the Contraception Choices website was not enough to help more women use the most reliable contraception methods.



# Scientific summary

## Background

Control of fertility is crucial to the health and well-being of women, but unintended pregnancy remains common and costly for both health services and individuals. In the UK, despite a range of freely available effective contraceptive methods, abortion rates have changed little over two decades (at around 190,000 per year for women resident in England and Wales).

Preventing unintended pregnancy involves many processes, including timely education, awareness and socially patterned behaviours, that lead women to seek, choose and use contraception consistently and correctly. Health services have a key role to play by supporting women to choose and use an appropriate method that best meets their needs, but many women are still not aware of the range of methods available to them. The combined oral contraceptive pill and condoms are well known and widely used, but are not the most effective contraceptive methods. Long-acting reversible contraception, that is intrauterine devices, intrauterine systems, implants and injections, is over 20 times more effective than oral contraceptives and condoms, but these methods are less well known to women and may not even be discussed in settings without the capacity to provide them.

Increasingly, women turn to online sources of information on health care. However, online information is of variable quality and misperceptions about contraception are common. This study aimed to develop and test the effectiveness of an interactive website to aid informed choice of contraceptive method.

## Phase I objectives

1. To systematically review evidence on individual-level education or decision aid interventions relating to acceptability and uptake of and adherence to contraception (including underpinning theories, and user and provider views).
2. To obtain the views of contraceptive service users and providers in five settings (general practice, sexual and reproductive health services, abortion services, maternity services and community pharmacies), relating to access to and acceptability and uptake of contraception.
3. To apply the information from objectives 1 and 2 to identify the key design issues and content for an interactive digital intervention or website.
4. To co-design the website with young women and health-care professionals.

## Phase II objectives

5. To conduct a randomised feasibility trial of the website in five different service settings (general practice, sexual and reproductive health services, abortion services, maternity services and community pharmacies).
6. To assess, through qualitative process evaluation, the acceptability of the trial procedures, women's views of the intervention itself and NHS implementation considerations.
7. To write a protocol for a definitive trial of an interactive digital intervention to aid informed choice of contraception and the acceptability and uptake of and adherence to long-acting reversible contraception methods in young women.

## Methods

### Overview

In Phase I, we completed three systematic literature reviews, a review of YouTube (YouTube, LLC, San Bruno, CA, USA) videos and discussion threads about contraception, and conducted focus groups and interviews with young women to explore barriers, benefits, concerns, myths and misperceptions relating to contraception. In addition, we sought the views of health professionals and held an expert workshop. From these findings, we developed a logic model to guide design of a new interactive website: Contraception Choices [URL: [www.contraceptionchoices.org](http://www.contraceptionchoices.org) (accessed January 2020)]. The website was designed through an iterative process of consultation with young women and a commercial software company. In Phase II, we evaluated the effectiveness of the website in an individually randomised trial using qualitative and quantitative methods.

### Recruitment and trial methodology

For both phases, women aged 15–30 years were recruited from clinical sites representing the settings in which the great majority of contraceptive consultations occur: a general practice (Clerkenwell, North East London), sexual health services (Brook, Euston and the Margaret Pyke Centre), a maternity service (Ashford and St Peter's Hospitals NHS Foundation Trust), a community pharmacy (Green Light Pharmacy London) and an abortion service (British Pregnancy Advisory Service, East London).

In the feasibility trial, women were recruited in clinic by a researcher using a tablet computer. The trial software was designed to enable participants to go through the steps of screening, consent, automatic randomisation, data collection and website viewing without assistance, although in practice this process was nearly always supported by a researcher. Participants allocated to the intervention condition were immediately directed to the Contraception Choices website. Those allocated to the control condition were invited to view the website at the end of the trial in 6 months' time. All participants were followed up by e-mail, text or mobile phone at 3 and 6 months, and asked to complete an online questionnaire for outcome data. Free-text comments from the questionnaire were used for qualitative analysis.

The popularity of the Contraception Choices website among young women and the demand from contraception providers to disseminate the website led to the feasibility trial becoming a Phase III, or efficacy, trial. To achieve this, we increased the recruitment target – from 400 in the feasibility trial to 930 in the efficacy trial – and changed the primary outcome from a feasibility measure (6-month follow-up rate) to clinical outcomes that were originally secondary outcomes in the feasibility trial. This resulted in two primary outcomes for the efficacy trial: use of long-acting reversible contraception at 6 months and satisfaction with contraceptive method at 6 months. A sample size of 930 was estimated to be sufficient to detect (with 82% power) an increase in uptake of long-acting methods from 35% to 47%, assuming a follow-up rate of 70%. We also conducted a budget impact analysis of the website and contraception, reporting the total costs to each payer [NHS (primary care vs. secondary care), local government, private and out of pocket] and the total cost of contraception and pregnancy outcomes for a range of population sizes.

Rapid expansion in recruitment was achieved by recruiting women online (rather than in clinic) from one of the study sites, the Margaret Pyke Centre. When women request an appointment for contraception at this clinic, they are routinely directed to the trust website to book their appointment. Once an appointment is booked, the patient receives a text message confirming the date and time of the clinic appointment. For the trial, we inserted into the routine text an invitation to take part in contraception research by clicking on a hyperlink, which took women to the trial recruitment home page. From this point, the trial procedures were the same as for women recruited in clinic.

In effect, by changing from a feasibility trial to an efficacy trial, we completed the trial referred to in objective 7 (see *Phase II objectives*) rather than writing a protocol for it.

## Results from Phase I

### *Review of published literature*

Our meta-synthesis of 18 systematic reviews of factors affecting choice and use of contraception showed that pathways to successful contraception choice and use are complex and strongly shaped by factors that are often outside the control of individual women. Globally, use of contraception is influenced by the perceived likelihood and appeal of pregnancy, relationship status, knowledge, beliefs, and perceptions of side effects and health risks. Male partners have a strong influence on contraception uptake, as do the views and experiences of peers, and family members' expectations. Lack of education and poverty are linked with low contraception use, and social and cultural norms influence expectations of family size and timing. Contraception use also depends on the availability of methods, the accessibility, confidentiality and costs of health services, and attitudes, behaviour and skills of health-care personnel.

Our second systematic review of trials of interactive digital interventions for contraception choice and use found one significantly positive trial and showed that digital interventions for contraception are feasible and promising, and that offering access in clinic waiting rooms is appropriate.

Our third review of 21 systematic reviews of face-to-face interventions for contraception and theories about contraception decision-making included a meta-analysis of eight randomised controlled trials (which found that motivational interviewing significantly increased effective use of contraception) and a synthesis of eight trials of educational interventions (which found educational interventions to be effective for knowledge acquisition, but not for change in attitudes or behaviour). Goal-setting and self-monitoring are important elements of many successful interventions.

### *Women's views: qualitative fieldwork*

Qualitative data, from focus groups, interviews with 74 women and review of 35 YouTube videos and discussion threads, were coded and categorised by theme and subtheme. The key findings can be summarised as follows:

- The most commonly expressed concern about contraception was the 'unnaturalness' of hormones contained in hormonal contraceptive methods.
- Other commonly expressed concerns or anxiety about contraception related to infertility, irregular bleeding, having no periods, risk of cancer and side effects.
- Many women think it is unhealthy to skip periods.
- Many women think their bodies need a break from contraception.
- Women do not have a good understanding of contraceptive side effects.
- There is a strong tendency to underestimate contraceptive benefits and to overestimate contraceptive side effects.
- Partners' views are important to women.
- Women like seeing honest videos of other women talking about their experiences of contraception.
- Women dislike seeing a lot of text on a website and would prefer to have options to view more information if they wish to know more.

### *Views of health-care providers*

The interviews with health-care professionals gave rise to all the same issues raised by women themselves in relation to contraceptive knowledge, concerns and misperceptions. Other issues explored in interviews with health-care professionals were practical ones relating to the feasibility trial design and the practicalities of recruiting in clinics, such as access to Wi-Fi.

The Contraception Choices website draws on all these findings to provide information that addresses women's concerns about and barriers to uptake of contraception, including, for example, a dynamic infographic to compare the effectiveness of different methods. Young women's perspectives and concerns are integral to the design and content, which acknowledge explicitly the challenges that

women often face, and offer straightforward advice in a way that does not judge women for their choices or situations. A key feature is an interactive decision tool that takes the user through a series of questions designed to identify appropriate method(s) that best suit individual preferences (e.g. for a non-hormonal method, one that does not require insertion by a health-care professional or one that is invisible), and then generates three suitable contraceptive options, with brief annotation. The three options can then be sent by e-mail or text to a mobile for further personal consideration, discussion with friends and family or discussion during a contraceptive consultation (although contraceptive consultations were not assessed in the trial).

## Results from Phase II: randomised trial

### *Quantitative and qualitative findings*

The first participant was randomised on 4 July 2017 and the last on 22 December 2017. The first woman was recruited through the online central booking service on 31 October 2017 and the last on 22 December 2017. Recruitment online was much faster than in the clinics. It took approximately 6 months to recruit 400 women from the clinic sites, as originally planned (we recruited 530 women via the online booking system in just over 7 weeks).

Two-thirds of participants were from white ethnic groups, half were educated to degree level and four-fifths reported English as their first language. Ten per cent were pregnant, whereas 90% indicated a current need for contraception to avoid unintended pregnancy. The most common method at baseline was the pill, followed by long-acting reversible contraception methods. Around two-thirds of women were satisfied with their current method at baseline.

In total, 927 women were randomised to the website group ( $n = 464$ ) or to the control group ( $n = 463$ ), of whom 739 (80%) provided follow-up data at 6 months. A total of 786 women (86%) provided data at 3 or 6 months, or at both time points, and were included in the analysis of primary outcomes with imputation. Written feedback about the website was provided by more than four-fifths of trial participants in the intervention group. The main themes were about the website information and content, the design and format, interaction with health professionals, being part of the study and a range of impacts of the website. The last theme included switching to another method, changing behaviour as a result of correcting a misperception about contraception, personal sexual responsibility, discussing the website with others and barriers to accessing contraception. Apart from barriers to access, comments were strikingly positive and appeared to affirm the purpose of the website.

Across both study arms, satisfaction with method of contraception improved from around two-thirds at baseline to four-fifths at follow-up. There was no statistically significant difference between intervention and control groups in the proportion of women using long-acting reversible contraception at 6 months [30.4% intervention vs. 31.0% control, adjusted odds ratio after imputation 0.87 (95% confidence interval 0.60 to 1.27)], nor in level of satisfaction with contraceptive method [proportion being 'satisfied' or 'very satisfied', 82.6% intervention vs. 82.1% control, adjusted ordinal odds ratio 0.93 (95% confidence interval 0.69 to 1.26) based on the five ordered responses]. In the budget impact analysis, there was no statistically significant difference between the two groups in publicly funded contraception costs excluding pregnancy (£3.67, 95% confidence interval -£18.17 to £28.56) or including pregnancy (£73.65, 95% confidence interval -£46.38 to £192.40) or private out-of-pocket costs (£11.19, 95% confidence interval -£2.84 to £26.72).

## Conclusions

The Contraception Choices website was popular among young women because of its design, presentation of trustworthy information and guidance in choosing a method tailored to individual

preferences. However, it was not associated with any statistically significant difference in use of long-acting reversible contraception or satisfaction with contraceptive method at 6 months. Our systematic reviews confirmed multiple factors affecting women's choice and use of contraception, which go beyond informed choice. The lack of effect on clinical outcomes in this trial, despite highly positive feedback from participants, highlights a gap between improving delivery of personalised information and impact on contraceptive use. We hypothesise that this gap can be narrowed by shared reference to the website between patients and health-care professionals during contraception consultations. Contraception providers are keen to promote the website. The priority for further research is to determine whether or not use of the website during contraceptive consultations improves the quality of consultation and thereby clinical or service outcomes, ideally over a follow-up period of at least 1 year.

## Trial registration

This trial is registered as ISRCTN13247829.

## Funding

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 24, No. 56. See the NIHR Journals Library website for further project information.





# Chapter 1 Background

Control of fertility is crucial to the health and well-being of women, but unintended pregnancy remains common and costly for both health services and individuals. In the UK, despite a range of freely available effective contraceptive methods, abortion rates have changed little over two decades (at around 190,000 per year for women resident in England and Wales).<sup>1</sup> Despite a national teenage pregnancy strategy and recent fall in conceptions among those aged < 18 years, England still has the highest rate of teenage pregnancy in western Europe. A key report on the economics of sexual health concluded that it should be feasible to improve contraception and abortion services in ways that better meet the preferences of service users and that this could lead to a net saving (largely from fewer unintended pregnancies and reduced delay in abortion) of up to £1B over 15 years.<sup>2</sup>

Although avoidance of unintended pregnancy may be viewed as a shared responsibility between sexual partners, the burden of decision and action more often remains with women. Preventing unintended pregnancy involves many processes, including timely education, awareness and socially patterned behaviours that lead women to seek, choose and use contraception consistently and correctly. Health services have a key role in supporting women to choose and use an appropriate method that best meets their needs. However, many women are still not aware of the range of different methods available to them. There are widespread myths about contraception (e.g. fears about impact on future fertility, weight gain or the significance of amenorrhoea). The combined oral contraceptive pill and condoms are well known and widely used – by around half of all women using contraception – but they are not the most effective contraceptive methods.

Long-acting reversible contraception (LARC) methods, including copper intrauterine devices, progestogen-only intrauterine systems, progestogen-only injectable contraceptives and progestogen-only subdermal implants, offer women the most effective protection against pregnancy. Women who use oral contraceptive pills, the contraceptive patch or vaginal ring have a 20 times higher failure rate than women who use LARC methods.<sup>3</sup> More than a decade ago, the National Institute for Health and Care Excellence (NICE) concluded that increasing uptake of LARC is more cost-effective in reducing unintended pregnancy than the contraceptive pill or condoms, even at 1 year.<sup>4</sup> At that time (2005), estimated uptake of LARC in the UK was low, at 8% (2003/4 data), compared with 25% for the oral contraceptive pill and 23% for male condoms. Since then, uptake of LARC has increased, to 12% in the population in 2008/9 and to 41% by 2013, in women attending community contraceptive clinics.<sup>5</sup> Even in specialist community services, younger women are less likely to use LARC (24% in those aged < 30 years) than older women.

There are multiple pathways by which women get information about contraception and choose a method. The main sources of information are the internet, family and friends, school relationships and sex education, general practitioners (GPs), community pharmacies, and sexual and reproductive health services. However, not all of these sources provide information on LARC and uptake of LARC is limited by the number of appropriately trained doctors or nurses to fit them. It is understood that many general practices, which are the source most commonly used by women for contraception,<sup>6</sup> have little or no capacity for fitting and therefore rely on referral to specialist contraceptive services. Effective interventions are needed that expand women's choice of more effective methods of contraception, and increase uptake in a variety of settings.

Current standard care pathways for contraception vary considerably within and between different settings. Some services provide leaflets (e.g. the Family Planning Association) explaining the different methods, but the extent to which such leaflets are read, understood or help women reach an informed decision about contraceptive method is unclear. The quality of face-to-face consultation varies widely between different health-care providers with different skills, competencies and experience. The evidence base for improving contraceptive uptake and adherence through better face-to-face

consultations is slim and mostly disappointing;<sup>7-9</sup> our population-based study (funded by the UK Medical Research Council) of why women stop or switch contraceptive methods concluded that traditional consultation with a doctor or nurse in clinic has only modest influence on women's contraceptive decisions.

Health care in the UK is undergoing a health informatics revolution. The vast majority of young people have access to digital technology, which offers huge potential for health promotion. Recent data from the Office for National Statistics indicate that 99% of 16- to 24-year-olds have accessed the internet and 88% use it daily.<sup>10</sup> We know that younger women are likely to turn to digital resources for information on contraception.<sup>11</sup> For the proposed study, we therefore explored the use of interactive digital interventions (IDIs) that provide information and decision support for contraceptive choices.<sup>12-15</sup> IDIs may be available directly to users for self-guided use, or available with remote or face-to-face human support. They may be delivered by any digital medium, including the internet, mobile phone and handheld computers. Access can be private and self-paced, and programmes can be tailored according to individual characteristics. Digital interventions are effective at increasing knowledge of emergency contraception<sup>16</sup> and there is evidence of effect on sexual behaviour,<sup>12</sup> contraceptive choice and adherence.<sup>13-15</sup> However, we are not aware of any services in the UK that currently provide IDIs to support women's contraceptive decision-making.

### Study aims and objectives

The original aim of the study was to develop (Phase I) and test the feasibility (Phase II) of an intervention to increase the uptake of LARC methods in young women. LARC methods include intrauterine devices, intrauterine systems, subdermal implants and injectable contraception.

#### *Phase I objectives*

1. To systematically review evidence on individual-level education or decision aid interventions relating to acceptability, uptake and adherence to LARC, including underpinning theories and user and provider views [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)].
2. To obtain the views of contraceptive service users and providers in five settings (general practice, sexual and reproductive health services, abortion services, maternity services and community pharmacies) relating to access, acceptability and uptake of LARC.
3. To apply the information from objectives 1 and 2 to identify the key design issues and content for an IDI.
4. To co-design the IDI with young women and health-care professionals.

#### *Phase II objectives (including transition from a feasibility trial to an efficacy trial)*

The original objectives were:

5. To conduct a randomised feasibility trial of the IDI in five different service settings (general practice, sexual and reproductive health services, abortion services, maternity services and community pharmacies).
6. To assess, through qualitative process evaluation, the acceptability of the trial procedures, women's views of the intervention itself and NHS implementation considerations.
7. To write a protocol for a definitive trial of an IDI to improve informed choice of contraception and the acceptability, uptake and adherence to LARC methods in young women.

However, when we presented the website at conferences and seminars, the response from colleagues working in sexual and reproductive health was overwhelmingly positive. Service providers wanted to direct clients to the Contraception Choices website right away. The immediate demand for the website

convinced us that definitive testing in a subsequent efficacy trial, which would take years to complete, would be unwise and arguably unethical. Moreover, one site [the Margaret Pyke Centre (MPC)] wanted to promote the Contraception Choices website through its routine online system for booking clinic appointments. In response to this situation, we revised the feasibility trial protocol into an efficacy (Phase III) trial to examine the effect of the intervention on two clinical outcomes that were originally secondary outcomes in the feasibility trial: (1) use of a LARC method of contraception and (2) satisfaction with method of contraception at 6 months. The expansion in recruitment was achieved rapidly by recruiting women online (rather than in clinic) via the online booking system of the MPC (see below).

By changing from a feasibility trial to an efficacy trial, we completed the trial referred to in objective 7 [see *Phase II objectives (including transition from a feasibility trial to an efficacy trial)*], rather than writing a protocol for it.

## Study setting

The five main service providers of contraceptive advice and supplies provide the setting for the study: general practice, sexual and reproductive health services, community pharmacies, maternity services and abortion services. Together, these settings provide contraceptive care for the great majority of women in the UK. They include services that provide care for women at highest risk of unintended pregnancy (i.e. those who attend abortion services or seek emergency contraception through community pharmacies). These settings also provide care for different demographic subgroups within the population. Four out of five women go through childbirth, many of whom will require postpartum contraception to avoid an unintended pregnancy. Around 60% of women aged 16–44 years in Britain access contraception through general practice, whereas 23% of women attend community (sexual and reproductive health) clinics each year for contraception.<sup>6</sup>



# Chapter 2 Phase I: design and development of the website

## Overview of methods

We conducted three systematic reviews of the literature: (1) a review of reviews of factors influencing contraception choice and use, (2) a review of IDIs for contraception and (3) a review of face-to-face interventions for contraception and theoretical approaches to contraception decision-making.

We conducted six focus groups and 25 individual interviews to explore the views of 74 young women relating to contraception (access, acceptability, barriers and concerns), the design and content of the IDI (website) that we wished to develop, and their views on a future randomised controlled trial of such a website. We also reviewed 35 YouTube (YouTube, LLC, San Bruno, CA, USA) videos of women talking about contraception, including views expressed in video comment threads.

We synthesised the findings from the systematic reviews, women's views on YouTube and qualitative research with women and health professionals, and held an expert workshop to develop a trial-ready, self-guided website that presents a number of contraceptive options in response to input of women's preferences and concerns.

## Objective 1 (systematic reviews)

### *Systematic review 1: factors influencing contraception choice, uptake and use – a meta-synthesis of systematic reviews*

We synthesised the findings of 18 systematic reviews that were mostly of moderate or high quality [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)]. Factors affecting contraception use are remarkably similar among women in very different cultures and settings globally. Use of contraception is influenced by the perceived likelihood and appeal of pregnancy, and relationship status. Contraception choice and uptake is influenced by women's knowledge, beliefs and perceptions of side effects and health risks. Male partners have a strong influence on contraception uptake, as do the views and experiences of peers, and family members' expectations. Lack of education and poverty are linked with low contraception use, and social and cultural norms influence contraception and expectations of family size and timing. Contraception use also depends on the availability of methods, the accessibility, confidentiality and costs of health services, and attitudes, behaviour and skills of health-care personnel.

It is clear that contraception has remarkably far-reaching benefits and is highly cost-effective. However, our synthesis shows that women worldwide lack sufficient knowledge, capability and opportunity to make reproductive choices, and health-care systems often fail to provide access and informed choice. Urgent action is needed at many levels, involving a range of stakeholders, to enable informed family planning choice, and enhance the life chances of women and their families.

### *Systematic review 2: effectiveness of interactive digital interventions for contraception choice, uptake and use*

We completed a review of IDIs for contraception [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)]. Our extensive search using Cochrane Collaboration systematic review methods found five randomised controlled trials (RCTs) of IDIs for contraception and one cost-effectiveness analysis. One RCT demonstrated a statistically significant impact of an IDI plus a tailored printout in comparison with a generic contraception leaflet on uptake of an effective birth

control method [155/206 (75.2%) vs. 318/490 (64.9%);  $p = 0.008$ ]. The same trial showed no difference between tailored and generic printouts of IDI results. It was not possible to combine any of the RCT results because of the risk of bias, or too few trials in each analytic group. Cost-effectiveness analysis of a facilitated IDI predicted eight fewer births per 100 women at an unadjusted cost of US\$18,672 per prevented repeated birth.

We concluded that IDIs for contraception choice and use are feasible, and one high-quality RCT demonstrated a statistically significant impact on contraception choice. Access to, and information about, contraception is crucial to women's health and well-being. IDI could play an important role in providing convenient, reliable and tailored information about contraception and support for choice of method.

### ***Systematic review 3: effectiveness of face-to-face interventions for contraception and review of theoretical approaches to contraception decision-making***

We synthesised the findings of 21 systematic reviews of interventions for contraceptive choice and use. A meta-analysis of eight RCTs found that motivational interviewing significantly increased effective contraceptive use up to 4 months post intervention, but without a later reduction in pregnancy.<sup>17</sup> A synthesis of eight trials of educational interventions (including written materials, audiotapes, videotapes, interactive computer games, contraceptive decision aid and feedback from a provider) found that they are effective for knowledge acquisition, but not for change in attitudes or behaviour.<sup>18</sup> Multiple interventions (combining educational and contraceptive-promoting interventions) significantly lowered the risk of unintended pregnancy among adolescents.<sup>19</sup>

Contraception interventions based on theoretical constructs appear to be more effective than those not using theory.<sup>20</sup> Evidence suggests that the most effective behaviour change interventions are those that use multiple strategies to achieve multiple goals, including, for example, awareness, information transmission, skill development and supportive environments. Goal-setting and self-monitoring are important elements of many successful interventions. Behavioural interventions should be sensitive to audience and contextual factors, and recognise that most behaviour change is incremental and that maintenance of change usually requires continued and focused efforts.

## **Objective 2 (views of contraceptive service users and providers)**

### ***Recruitment***

We invited young women to share their views on computer-based interventions for sexual health via focus groups and interviews [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)]. Before recruiting from the five clinics involved in the project (a community pharmacy, a general practice, two sexual health centres, an abortion clinic and a maternity clinic), we first piloted the study materials with women who were students at University College London to make sure that the questions made sense and to test out the topic guide. Initially, we held a practice focus group with six students recruited from University College London to test the topic guide, make sure that women understood the questions and to make sure that the questions were suitable. Following this, recruitment started in each of the clinic sites. We placed posters [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)] in each clinic waiting room and leaflets (reduced-size poster) were handed out by reception staff and a researcher, inviting women to take part. Eligibility criteria included being aged 15–30 years, having the ability to converse in English language and give informed consent, and having an interest in taking part in contraceptive research.

Six focus groups were conducted with 44 women recruited from a sexual health clinic, a general practice and a pharmacy. In addition, individual interviews were conducted with five women recruited from a maternity hospital, 12 women from an abortion clinic and eight women from a young person's sexual health service. Individual interviews were preferred by women attending these clinics for the following

reasons: women from the maternity hospital found it inconvenient to return to a focus group, women from the abortion clinic did not want to be identified in the focus group as having had an abortion and women recruited from the young person's service were doubtful about returning for a focus group. The focus groups were conducted in university offices and the interviews were conducted in private rooms in each clinic. Each participant received a participant information sheet and provided written consent. Participants were offered £20 for taking part in the research, as a token of appreciation. Interviews were audio-recorded and transcribed, with participant permission.

### **Topic guide**

At each interview and focus group, women were made aware of the nature of the research and the confidentiality of their data. Ground rules for focus groups were also agreed at the outset. Questions on the topic guide centred around (1) views relating to access, acceptability, uptake and adherence to contraception; (2) views on proposed research design of a future RCT; and (3) design and content of an IDI for contraception decision-making [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)].

### **Analysis of qualitative data**

Thematic analysis was used to identify patterns and links within the qualitative data. The data were coded and categorised by theme and relationships between different elements of the text were identified. There was discussion of the findings and coding decisions within the team. The data set was analysed as a whole, seeking consistency or contradiction in themes within and across transcripts. Data were interpreted in the light of the context they were collected.

### **Key findings**

- The most commonly expressed concern about contraception was the 'unnaturalness' of hormones contained in hormonal contraceptive methods.
- Other commonly expressed concerns or anxiety about contraception related to infertility, irregular bleeding, having no periods, risk of cancer and side effects.
- Many women think that it is unhealthy to skip periods.
- Many women think that their bodies need a break from contraception.
- Women do not have a good understanding of contraceptive side effects.
- There is a strong tendency to underestimate contraceptive benefits and to overestimate contraceptive side effects.
- Partners' views are important to women.
- Women like seeing honest videos of other women talking about their experiences of contraception.
- Women dislike seeing a lot of text on a website and would prefer to have options to view more information if they wish to know more.

### **Views of health-care providers**

Each site had a project lead who was recruited for interview. Other members of staff were recruited and interviewed on the suggestion of the leads. Fourteen health-care professionals were interviewed in total: three specialist (sexual and reproductive health) doctors, two GPs, two pharmacists, five nurses, one midwife and one receptionist. The interviews with health-care professionals gave rise to all the same issues raised by women themselves in relation to contraceptive knowledge, concerns and misperceptions. Other issues explored in interviews with health-care professionals were practical ones relating to the feasibility trial design and the practicalities of recruiting in clinics, such as access to Wi-Fi [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)].

### **Objective 2 (review of YouTube videos)**

As noted in *Chapter 1*, women increasingly turn to digital sources for information on health care, and contraception is no exception. The social media platform YouTube provides a source of 'raw' opinions that can include misperceptions about contraception. We therefore examined the views and concerns

expressed by women on YouTube in order to identify common misperceptions that would need to be addressed through the Contraception Choices website.

A qualitative thematic analysis was conducted on contraceptive myths and misperceptions of 35 YouTube video clips and the video comment threads. The search terms used to locate videos were 'birth control story', 'birth control experience', 'contraception story', 'contraception experience', 'contraceptive pill', 'hormonal pill', 'combined pill', 'intrauterine device', 'IUD', 'intrauterine system', 'IUS', 'patch', 'birth control patch', 'contraceptive patch', 'depo injection', 'depo-provera', 'implant', 'contraceptive implant', 'nuvairing' and 'natural family planning'. Thirty-five video clips matched the search terms; these had been posted up to a maximum of 5 years before carrying out this analysis (i.e. from November 2010 onwards) and all comments used for analysis had been posted within the last 24 months (i.e. from November 2013 onwards). Data analysis was completed once data saturation was reached.

The most common myths and misperceptions featured on YouTube included a fear of hormones, weight gain, needing a break from contraception, cancer, infertility, whether or not contraception causes moodiness and whether or not it is natural to have periods. Analysis of comments also revealed women's concerns about what happens during appointments with clinicians, their fear of asking questions that might be considered 'stupid' and men's views with regard to women's contraceptive choices, which are rarely discussed in the published literature.

### **Objective 3 (applying the information from objectives 1 and 2 to identify the key design issues and content for an interactive website)**

#### ***Website aims***

The Contraception Choices website is designed to help women (and male partners) decide which method of contraception might suit them best, aiming to increase women's satisfaction with choice of contraception and to encourage uptake of more effective contraceptive methods. The website aims to facilitate informed decision-making, which was conceptualised as a voluntary, well-considered decision that an individual makes on the basis of information and understanding about the advantages and disadvantages of possible courses of action, made in accordance with the individual's beliefs.<sup>21</sup> Enacting a decision for contraception use will depend on factors outside women's control (e.g. access to health care, availability of a chosen method, and attitudes of partners and others).

Contraception Choices takes as a starting point the concerns that influence women's choices, and aims to provide honest information on the advantages and disadvantages of a range of contraception methods, featuring a decision-making tool from which tailored suggestions are presented, based on individual users' priorities and preferences.

#### ***Guiding principles underpinning the Contraception Choices website***

The website content is written from a sexual and reproductive rights perspective (i.e. people have a right to honest, straightforward information and freedom of choice regarding contraception, reproductive decisions and sexual well-being). The team believe that it is a woman's choice if and when they get pregnant (acknowledging that there are many influences on this choice, including partners, family, community and religion). We also believe that it is up to women to decide which method of contraception suits them, and that health professionals' role is to facilitate an informed choice without pressure or judgement.<sup>22</sup>

#### ***Understanding the context and complexity of contraceptive decision-making***

To understand the context and complexity of contraception decisions, we conducted systematic literature reviews, carried out qualitative fieldwork with the target website user group (women aged 15–30 years) and held an expert (health professional) website content workshop. The whole process is described in the following sections.



## Literature review 1: factors influencing contraception choice, uptake and use

### **Findings**

We synthesised the findings of 18 systematic reviews, which showed that pathways to successful contraception choice and use are complex, and strongly shaped by factors that are often outside individual women's control. Use of contraception is influenced by the perceived likelihood and appeal of pregnancy, relationship status, knowledge, beliefs, and perceptions of side effects and health risks. Male partners have a strong influence on contraception uptake, as do the views and experiences of peers and family members' expectations. Lack of education and poverty are linked with low contraception use, and social and cultural norms influence expectations of family size and timing. Contraception use also depends on the availability of methods, the accessibility, confidentiality and costs of health services, and attitudes, behaviour and skills of health-care personnel.

### **Implications for Contraception Choices website design**

The website addresses women's concerns in several different ways: succinct text ('Contraceptive Methods'), question and answer format ('Frequently Asked Questions'), videos ('Video') and an interactive decision aid ('What's Right for Me?'). Most of the content addresses women's concerns and priorities, rather than the wider influences on women's decisions. However, a section for male partners addresses men's concerns about women's use of contraception ('Did you Know? For Men'). Two infographics acknowledge the complexity of factors that influence contraception choice, including method benefits and side effects, women's priorities, partner views, friends, family, the media, wider society and experiences with health-care professionals ('Challenges' and 'What Matters to Women?').

## Literature review 2: effectiveness of interactive digital interventions for contraception choice, uptake and use

### **Findings**

We located five RCTs and one health economic analysis of IDI for contraception choice.<sup>13-15,23-25</sup> One RCT<sup>13</sup> demonstrated a statistically significant impact of an IDI plus a tailored printout on uptake of an effective birth control method and another<sup>26</sup> showed a statistically significant impact in preventing unintended pregnancy. The other trials were small and of low quality.

### **Implications for Contraception Choices website design**

This review shows that digital interventions for contraception are feasible and promising, and that offering access in the waiting rooms of health-care facilities is appropriate. We incorporated a feature on the Contraception Choices website that allows users to export the personalised results of the What's Right for Me? decision tool via e-mail or text message for later reference.

## Literature review 3: effectiveness of face-to-face interventions for contraception and review of theoretical approaches to contraception decision-making

### **Findings**

We synthesised the findings of 21 systematic reviews of interventions for contraceptive choice and use. A meta-analysis of eight RCTs found that motivational interviewing significantly increased effective contraceptive use up to 4 months post intervention, but without a later reduction in pregnancy.<sup>17</sup> A synthesis of eight trials of educational interventions (including written materials, audiotapes, videotapes, interactive computer games, contraceptive decision aid and feedback from a provider) found that they are effective for knowledge acquisition, but not for change in attitudes or behaviour.<sup>18</sup> Multiple interventions (combining educational and contraceptive-promoting interventions) significantly lowered the risk of unintended pregnancy among adolescents.<sup>19</sup>

Contraception interventions based on theoretical constructs appear to be more effective than those not using theory.<sup>20</sup> Evidence suggests that the most effective behaviour change interventions are those

that use multiple strategies to achieve multiple goals, including, for example, awareness, information transmission, skill development and supportive environments. Goal-setting and self-monitoring are important elements of many successful interventions. Behavioural interventions should be sensitive to audience and contextual factors, and recognise that most behaviour change is incremental and that maintenance of change usually requires continued and focused efforts.

### ***Implications for Contraception Choices website design***

The website content draws on several different theoretical models to prompt active, informed choice of contraceptive method (see *Table 1*). A key feature of motivational interviewing is that counselling starts with people's own perspectives and seeks to help people find their own motivations for change. Young women's perspectives and concerns are integral to the Contraception Choices website design and content, and advice is offered in a way that does not judge or blame women for their choices or situations.

### **Qualitative fieldwork**

As described above, our qualitative fieldwork focused on exploring women's views and experiences of contraception, to understand their concerns, beliefs, myths and misperceptions, and views on how to harness the potential benefits of different contraceptive methods. We conducted interviews and focus groups with 74 young women and reviewed 35 YouTube videos and discussion threads (see *Key findings*).

### ***Implications for Contraception Choices website design***

All of these themes were reflected in the website content and design, addressing women's beliefs, concerns, myths, misperceptions, contraception benefits and women's views on design options, including section titles, colours, logo and interactive features. The website offers information using written, video-recorded and pictorial methods (including infographics) to address different preferences for communication of information and literacy. Text was presented in small chunks wherever possible (e.g. bullet points), with more information available as wanted.

### **Hypothesised mechanisms of change**

The main issue addressed by the website is the risk of unwanted or unplanned pregnancy. Our logic model shows how the website content addresses factors that contribute to this, including a lack of accurate knowledge on contraceptive method choices; worry about side effects or harms; misperceptions about methods and their use; and little knowledge of or faith in the potential benefits of contraception [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)]. The website aims to present relevant information; to address worry about procedures or side effects; to facilitate women's ability to weigh up pros and cons of different methods (or no method); and to increase motivation to find (and obtain) a suitable method.

A key step in obtaining most contraception methods is to consult a health-care professional (either in person or online). The website exports a record of the three personal contraceptive method suggestions by e-mail or by text message to users' mobile phones, if wanted. This is to facilitate recall and can be used as a prompt for conversations with clinicians. It was hypothesised that interaction with the Contraception Choices website before a clinical encounter could result in more informed discussions with clinicians, and shared decision-making, leading to contraception choices that are more likely to be effective and more likely to be satisfactory (if women are more actively involved in making choices). The website offers a clinic finder.

## **Objective 4 (co-developing the website with young women and professionals)**

### ***Expert (health professional) intervention content workshop***

We held an expert workshop, inviting sexual health clinicians, researchers and e-health experts to contribute their views on the design of an IDI to help young women make contraceptive choices.

Participants, who included Contraception Choices research team members and other experts in the field, were asked to propose and debate design features of a digital intervention, to try to reach a consensus [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)]. We summarised debates on a Microsoft Excel® worksheet (Microsoft Corporation, Redmond, WA, USA) to assess the pros and cons of each design decision. Decisions were made by the research team on the basis of congruence with the intervention aims, practicality and/or resources needed (for intervention development or for future maintenance). User views were sought for website design and content once draft ideas had been conceptualised.

### ***Clinical content of the website***

Information about individual contraceptive methods derives from guidelines produced by the UK Faculty of Sexual and Reproductive Healthcare<sup>27</sup> and textbooks.<sup>22,28</sup> The website authors (Julia V Bailey and Lisa Walton) are sexual health professionals who have extensive experience of prescribing contraception and addressing women's concerns and queries in clinic settings.

### ***Website development process***

We recruited a software company, Moore-Wilson (Salisbury, UK), following a competitive tendering process. Moore-Wilson drew up website design ideas (wireframes) following team discussions about possible options. Front-running designs were discussed and refined by women in focus groups run by Anasztazia Gubijer, with design and content also discussed via an e-mail user group. Website content was written by Julia V Bailey and Lisa Walton first in Microsoft Word documents (Microsoft Corporation, Redmond, WA, USA) and/or directly into the website content management system. For each content feature, there were several design iterations involving the software company, the research team and target users.

For the video section, we sought freely available YouTube videos that provided accurate information about different contraception methods. We did not find suitable videos for every method, or for all of women's main concerns, so we shot our own films in a digital media studio. We filmed individual interviews with six young women who described their own experiences of using contraception. Julia V Bailey then noted the exact time codes for each topic discussed (i.e. specific benefit or problem with a method). Selected interview excerpts were then played back to clinicians who were filmed responding to each concern with advice from their clinical experience.

A scoring algorithm was developed by Julia V Bailey for the 'What's right for me?' decision aid, based on evidence of the likelihood of experiencing a particular effect or side effect with each contraception method, in terms of amenorrhoea or regular periods, lighter or less painful periods, impact on acne or premenstrual syndrome, effort involved in remembering a method, presence of hormones and immediate reversibility. If methods scored exactly the same following women's choices within the tool, scores were weighted so that the more effective methods were displayed first.

To see the final Contraception Choices website please visit [www.contraceptionchoices.org](http://www.contraceptionchoices.org) (accessed January 2020).

### ***Information on contraceptive methods***

The 'Contraceptive Methods' section features information on pros and cons of methods presented in bullet points, with more information available on benefits and side effects, and tips on how to use each method.

The 'Effectiveness' infographic is interactive, displaying the risk of pregnancy for 'typical use' of each contraceptive method and comparing with risk of pregnancy if using no contraception.

The 'Video' section features educational YouTube videos and short films of young women expressing their views and experiences of contraception, followed by clinician explanations on specific topics.

The ‘Did you Know?’ section addresses women’s most common concerns about contraception.

The ‘Frequently Asked Questions’ section is organised as answers to questions, which show which methods have specific benefits (e.g. lighter, less painful periods).

**Interactive tailored decision aid**

The ‘What’s Right for Me?’ tailored decision aid takes into account women’s priorities concerning contraception attributes and potential benefits to suggest three methods of contraception to suit their preferences. Hovering over the image of each method offers a very succinct summary of method attributes, and the tool allows users to see the effect of their choices after each question. For example, selecting ‘regular periods’ highlights the methods that are compatible with regular periods and fades out the methods that can alter the menstrual cycle. The top three results are presented side by side, allowing comparison of the main contraception attributes. If a suggested method is ‘binned’, the next in the list will be displayed. Results can be exported by e-mail or by text message if a user wishes.

**Further information section**

Under the tab ‘COVID-19’, the *Contraception Choices* website features links to several other websites, such as Find a Sexual Health Service on the NHS website [[www.nhs.uk/service-search/other-services/Sexual-health-information-and-support/LocationSearch/734](http://www.nhs.uk/service-search/other-services/Sexual-health-information-and-support/LocationSearch/734)] (accessed 18 June 2020).

**Additional evaluation of Contraception Choices**

In parallel with the Phase II study, a further formative evaluation of *Contraception Choices* was conducted by a Master of Science (MSc) student, Xia Zhou, who was studying human–computer interaction. This study showed that *Contraception Choices* compared favourably (on qualitative measures) with other web-based tools that support contraception decision-making and highlighted a few areas in which the interaction design could potentially be improved. However, as this was a small-scale study, the findings need further validation, which was outside the scope of this project. See [https://uclic.ucl.ac.uk/content/2-study/4-current-taught-course/1-distinction-projects/1-17/zhou\\_xia\\_2017.pdf](https://uclic.ucl.ac.uk/content/2-study/4-current-taught-course/1-distinction-projects/1-17/zhou_xia_2017.pdf) (accessed 18 June 2020) [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)].

The findings from the following sources of evidence therefore informed the *Contraception Choices* website content (Table 1):

- systematic literature reviews
- women’s priorities and concerns (YouTube study and qualitative fieldwork)
- user design preferences
- clinical evidence and guidelines: UK Medical Eligibility Criteria for Contraceptive Use ([www.fsrh.org/ukmec/](http://www.fsrh.org/ukmec/)) and Faculty of Sexual and Reproductive Healthcare clinical guidelines ([www.fsrh.org/standards-and-guidance/current-clinical-guidance/](http://www.fsrh.org/standards-and-guidance/current-clinical-guidance/))
- clinical expertise.

TABLE 1 Rationale for *Contraception Choices* website content

Issue to address	Website section or feature	Intended outcome
Need for accurate, balanced information on contraceptive method choices; concerns about side effects or harms; myths and misperceptions	Clearly presented information on 12 contraception methods, explaining pros and cons, benefits and mode of action [URL: <a href="http://www.contraceptionchoices.org/contraceptive-methods">www.contraceptionchoices.org/contraceptive-methods</a> (accessed January 2020)]	Accurate knowledge to support informed choice  Less worry about potential side effects or harms
Inaccurate perceptions of the effectiveness of different contraceptive methods	Interactive infographic showing the likelihood of pregnancy with each method [URL: <a href="http://www.contraceptionchoices.org/infographic">www.contraceptionchoices.org/infographic</a> (accessed January 2020)]	Accurate portrayal of risk of pregnancy in a form that people can understand, to support informed choice

TABLE 1 Rationale for Contraception Choices website content (continued)

Issue to address	Website section or feature	Intended outcome
There are many contraception methods and it is difficult to retain comparative information	'Compare all' contraception methods table with extra explanation on hovering [URL: <a href="http://www.contraceptionchoices.org/whats-right-for-me/table">www.contraceptionchoices.org/whats-right-for-me/table</a> (accessed January 2020)]	Better ability to assess pros and cons of methods, to support informed choice by allowing easy comparison of method attributes
Peer views and experiences influence women's contraception choices. Many women seek peer views online. Women have mixed experiences and trust in clinicians	Videos featuring young women and clinicians: personal experiences of young women who had used a variety of contraceptive methods; health-care professional responses to women's concerns within the same video	To acknowledge women's concerns through voices they trust (peers and clinicians) and to show how concerns might be addressed. Less worry about potential side effects or harms
Little knowledge or faith in the potential benefits of contraception. Disproportionate worry about side effects or harms	'Did you Know?' [URL: <a href="http://www.contraceptionchoices.org/did-you-know">www.contraceptionchoices.org/did-you-know</a> (accessed January 2020)] and 'Frequently Asked Questions' [URL: <a href="http://www.contraceptionchoices.org/faqs">www.contraceptionchoices.org/faqs</a> (accessed January 2020)] sections. Honest information regarding benefits and concerns about contraception, to acknowledge and address women's concerns and to showcase benefits of different methods	Accurate knowledge. Less worry about potential side effects or harms
Choosing and using contraception can be complex and difficult, and can be out of women's immediate control	'Challenges' infographic [URL: <a href="http://www.contraceptionchoices.org/did-you-know/challenges">www.contraceptionchoices.org/did-you-know/challenges</a> (accessed January 2020)] and 'What Matters to Women' infographic [URL: <a href="http://www.contraceptionchoices.org/did-you-know/how-body-works">www.contraceptionchoices.org/did-you-know/how-body-works</a> (accessed January 2020)]	Acknowledging that choosing and using contraception can be difficult. To draw attention to wider factors that may be influencing women's decisions
	Infographics that acknowledge key factors that influence contraception choice and use: women's priorities, method attributes, partner influence, friends, family, media, culture and experience in clinics	
Half-hearted use or non-use of contraception (through lack of access to informed choice)	What's Right for Me? decision tool. Tailored decision aid, for users to input their preferences in terms of contraception attributes. Three 'best-fit' options are offered and compared side by side	Decision-aid to simplify the complex process of weighing up multiple pros and cons, offering information that is personally relevant. Increased motivation to seek a more suitable method
To provide a personalised record of contraception choice suggestions	Top three contraceptive method suggestions. Three top choices of method compared side by side and e-mailed or texted, if wanted	To facilitate recall of choices, and as a prompt for more informed discussions with clinicians
Most contraception methods need to be prescribed or fitted by clinicians	Clinic finder. Information on abortion services and support for domestic abuse	To support the next steps in acquiring a contraceptive method (i.e. clinic attendance). Resources for women seeking abortion or support with intimate partner abuse



## Chapter 3 Phase II: evaluation trial of the website

### Methods

#### *Original feasibility trial design (objectives 5 and 6)*

This was an individually randomised, parallel-group trial.

#### *Setting*

Study sites were recruited to represent the health-care settings that provide the great majority of contraceptive care in the UK (Table 2).

#### *Inclusion criteria*

Women were included if they were aged 15–30 years with a need for current or future contraception, were attending one of the study sites, were able to read English, and had an active e-mail account and access to the internet.

#### *Exclusion criteria*

Women were excluded if they were unable to provide informed consent (e.g. severe learning difficulties) or if they needed a language advocate to understand English, as the intervention content was intended to be accessed in private.

### The intervention

At the end of Phase I, using evidence from systematic reviews, women's views on social media, an expert workshop, and interviews with women and health professionals, we had created a trial-ready, self-guided website that presents a number of contraceptive options in response to input of women's preferences and concerns. The website has four main components: (1) general information on contraception

TABLE 2 Study sites

Category	Name	Details
Sexual and reproductive health service	MPC	Capper Street, London, UK
Sexual and reproductive health service for young people	Brook	Brook clinic, Euston, London, UK
Abortion service	BPAS	Romford Road, Stratford, London, UK
Community pharmacy	Green Light Pharmacy (Shepherd's Bush)	Uxbridge Road, London, UK
Maternity service	Ashford and St Peter's Hospitals NHS Foundation Trust <sup>a</sup>	St Peter's Hospital, Guildford Road, Chertsey, Surrey, UK
General practice	General practice (Camden and Islington)	Clerkenwell Medical Practice, Finsbury Health Centre, Pine Street, London, UK

BPAS, British Pregnancy Advisory Service.

<sup>a</sup> We originally recruited the maternity service at University College London Hospitals NHS Foundation Trust, but on finding that relatively few women under the age of 30 years attend this service, we switched to Ashford and St Peter's Hospital, as this serves a younger pregnant population.

and method-specific information, including contraceptive benefits, side effects and other common concerns; (2) an interactive tool to help women choose a method of contraception, which provides individually tailored results; (3) videos of women and health professionals discussing contraceptive experiences, concerns and misperceptions; and (4) a page offering a link to NHS clinic finders and other useful resources, such as further information on sexual health, and websites offering support and advice about sexual abuse.

## Outcome measures

### Primary outcome

- Follow-up rate at 6 months.

### Secondary outcomes: quantitative

- Recruitment rate. Measured via the trial website as the time taken to recruit (up to 80) women at each site.
- Effectiveness of contraceptive method in use at 6 months. Measured by response to study outcome questionnaire and grouped as follows: from least to most effective; no method; withdrawal or natural method; condoms or diaphragm; pill, patch or ring; LARC or sterilisation.
- Change in method between baseline and 6 months, indicating whether any change is to a method of greater, lesser or similar effectiveness (based on grouping above).
- Pregnancy by 6 months. Measured at 3 and 6 months by response to study outcome questionnaire.
- Sexually transmitted infection diagnosis by 6 months. Measured at 3 and 6 months by response to study outcome questionnaire.
- Health service and out-of-pocket costs for contraception and other sexual health services. Measured at 3 and 6 months by response to study outcome questionnaire.

### Secondary outcomes: qualitative

- Patient views and experience of the intervention and trial procedures, assessed through qualitative interviews at 2 weeks after randomisation with five women at each study site (total 25 interviews [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)]. The questions explored included:
  - Are the online trial procedures acceptable to participants? For example, the process of online registration and consent, the receipt of incentives, completing online questionnaires, contact and follow-up by e-mail and text?
  - What are women's views of the intervention?
  - How might trial procedures be improved to optimise retention in a full-scale trial?
- Provider views about impacts on the service and trial procedures, assessed through qualitative interviews with up to 15 key staff (up to three per site), sampling those who have roles in facilitating the study in each setting (e.g. receptionists, practice managers, nurses, midwives, doctors and pharmacists) [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)]. The areas explored included:
  - Are recruitment procedures acceptable to staff?
  - How might recruitment procedures be improved to optimise recruitment to a full-scale trial?
  - Staff views on the feasibility and usefulness of a contraception decision website in each clinic setting?



## Sample size

The original target sample size of 80 participants in each of the settings was based on estimating an expected follow-up rate at 6 months (primary outcome) of 70%, to within 10% precision [95% confidence interval (CI) 60% to 80%], for each setting. This sample size also provided 80% power to detect a statistically significant difference (at the 5% level) in the follow-up rate between two settings if the true difference is 22% (e.g. 59% vs. 81%). By pooling data across settings, this sample size would also provide 80% power to detect a statistically significant difference (at the 5% level) in the follow-up rate between the intervention and standard arms if the true difference is 15% (e.g. 62.5% vs. 77.5%). The expected follow-up rate was based on a previous sexual health study that recruited and followed up the participants online (Sexunzipped<sup>29</sup>).

## Baseline survey

Participants were asked to complete a short questionnaire at baseline before randomisation [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)]. This included:

- demographic data (age, ethnicity, highest completed level of education) and whether or not English was their first language
- current use of contraception, or reasons for non-use, including being pregnant, type of method [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)], from where the method was obtained, including whether or not obtained online and if paid for
- satisfaction with current contraception (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied)
- if ever used different methods (same list as current use)
- diagnosed sexually transmitted infections in the last 3 months [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)].

## Follow-up surveys

At follow-up, at 3 and 6 months, participants were asked what method of contraception they were using (including none) and how satisfied they were with the method; whether or not they had had a pregnancy and, if so, the outcome of the pregnancy (ongoing, gave birth, miscarried, terminated, or prefer not to say); and if they had a diagnosed sexually transmitted infection.

All participants were asked whether or not they had visited the website (control participants were asked to assess 'contamination') and if being in the study had resulted any good or bad effects on their life.

Intervention group participants only were asked how helpful the website was for getting useful information about contraception and how helpful it was for finding a method of contraception that is right for them; whether or not they had discussed the website with anyone, including a doctor or nurse, pharmacist, partner, family or friends; and what they liked or disliked about the website.

## Procedures: recruitment in clinics

Recruitment, completion of the baseline survey and randomisation were all accomplished online using bespoke trial software, but the process was initiated while the participant was attending one of the study clinics. Participants randomised to the intervention group were immediately given access to the website, whereas women randomised to the control group were thanked for their participation and

then received standard contraceptive care only. All women in both intervention and control groups were asked by automated e-mail to complete the same outcome questionnaires online at 3 and 6 months. The control group was offered access to the intervention website at the end of the study (after 6 months' follow-up).

On arrival at each study site, women were given a flyer about the trial by the reception or research staff with very brief information about the study, indicating the inclusion criteria. The same information was available on posters in waiting rooms and clinic rooms [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)]. Clinic staff were asked to direct women who were interested in the study to a member of research staff or directly to the tablet device.

In the feasibility trial, the website was displayed on a tablet computer as it was designed to be available in clinic and integrated into the clinic pathway, as well as being accessible online at any time. It is accessible on mobile phones as well as desktop computers. The trial software was set up to allow participants to go through the steps of screening, consent, automatic randomisation, data collection and intervention viewing without assistance from the staff, although in practice this process was nearly always guided by the researcher. We did not use individual identifications or passwords, as recruitment in a previous study of sexual health websites had been hampered by enrolment procedures that patients found onerous and time-consuming. Consequently, we streamlined the online trial software as much as possible and minimised the number of questions asked at baseline and follow-up [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)].

Participants who agreed to participate gave their contact details (compulsory e-mail address and optional telephone number and postal address) for follow-up surveys. They were given electronic vouchers for completing follow-up surveys (£5 for the survey at 3 months and £15 for the survey at 6 months). All follow-up e-mails included a link to allow participants to withdraw from the study, including one sent immediately after enrolment.

### Randomisation procedures

A randomisation list was generated by a random number-based algorithm in the computer software Stata® (StataCorp LP, College Station, TX, USA) and incorporated into the trial software program to allocate all participants to either the intervention group or the control group. The randomisation list was stratified by setting and using varying block sizes. Allocation was immediate (online) and concealed.

Participants allocated to the intervention condition were directed straight away to the Contraception Choices website. Those allocated to the control condition were notified that they had not been selected to view the website until the end of the trial. All participants were reminded that they would be contacted again in 3 and 6 months to gather follow-up data.

### Follow-up procedures

As described in *Figure 1*, follow-up was automated through e-mail and text messages. If there was no response to e-mails or texts, the researcher telephoned participants to remind them to complete the follow-up surveys:

- automated e-mail, with three further follow-up e-mails at weekly intervals
- two text messages (if mobile phone number supplied) at the same time as the last two e-mails
- three telephone calls (if mobile phone number supplied) in 1-week intervals after the final e-mail.




FIGURE 1 Follow-up procedures in feasibility trial.

## Study timeline

The planned duration of the feasibility trial was 15 months [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)]:

- 6 months' recruitment (based on the large number of patients attending each of the study sites, and an estimated proportion of 20–30% agreeing to take part, given previous experience of similar studies and the financial incentives offered)
- 6 months' follow-up
- 3 months' analysis of quantitative and qualitative data.

Phase I took longer than anticipated, largely because of the lengthy process of obtaining research permissions. During Phase II, we were awarded a 6-month no-cost extension when the feasibility trial changed to an efficacy trial.

### Trial process evaluation

In addition to obtaining women's views on the website itself, we assessed women's experiences of taking part in an online study of contraception. This formed an early part of the feasibility study and the findings were intended to inform the subsequent feasibility trial.

#### Aim

To explore women's experiences of taking part in an online study of a contraception website and to use the information to improve the subsequent trial design as appropriate.

#### Methods (trial procedures, rapid follow-up, then interviews)

We recruited 18 women from all the clinic sites to take part in an 'expedited' study of the website, followed by an interview to explore their experiences. Unlike the subsequent recruits, who were randomised to the intervention or control group, all of the early participants were assigned to the Contraception Choices website and followed up by e-mail 1 week after recruitment, rather than 3 and 6 months later. This method enabled us to gain information about the website and the trial procedures in a short time, so that we could make any necessary changes before starting the main recruitment. It also meant that participants had a shorter time period over which to recall their experiences, which should enhance the reliability of their recollections. As these early participants were not randomly allocated to the intervention or control group, they were not included in the randomised trial.

#### Findings

The main reason for agreeing to take part was an interest in finding out more about contraception. Participants found registering for the study on the tablet computer 'quick' and 'easy' and the information provided 'clearly written' so that they understood what the study was about and what they were agreeing to. Most participants felt that it was appropriate and acceptable to be approached about the study in a clinic waiting room. When asked what they felt about the topic of contraception and pregnancy, women commented that they were:

*Open to it ... like being in the clinic anyway, you kind of expect to, to talk about it ... it's quite comfortable ... it wasn't really that weird to talk about it.*

One participant recruited from the abortion service felt 'mixed' about being asked about contraception and pregnancy at the time:

*I don't really know I think I was quite mixed there because I was definitely like not, well I guess I was just like cursing myself at the time I was like this is something I should have thought about before.*

In general, participants did not have concerns about providing their contact details (telephone number and e-mail address) and understood that they were giving them so the research team could send them the follow-up questionnaire and contact them to arrange an interview. Once recruited, participants found it convenient to be contacted about the study by e-mail, text and telephone.

All participants, when asked, reported that they would take part in the study again.

#### Conclusions for the trial

Given the overall positive findings from these early recruits, we concluded that there was no need to make changes to the feasibility trial design.

## Transition from feasibility to efficacy trial (modified objective 7)

As noted above, the immediate popularity of the Contraception Choices website with young women and contraception providers convinced us to 'expand' the feasibility trial into an efficacy trial. To achieve this, we increased the recruitment target and changed the primary outcome from a feasibility measure (6-month follow-up rate) to clinical outcomes that were originally secondary outcomes in the feasibility trial, resulting in two primary outcomes: (1) use of LARC at 6 months and (2) satisfaction with contraceptive method at 6 months.

In addition to the 400 women recruited to the feasibility trial, we planned to recruit another 530 women from one site only, the MPC, via its routine online booking system. We estimated that a total of 930 participants would be sufficient to detect an (82% power) increase in uptake of long-acting methods from 35% to 47%, assuming a follow-up rate of 70%. No formal calculation was made for the other primary outcome – satisfaction with method.

When women request an appointment for contraception at MPC, they are routinely directed to the trust website to book their appointment. Once an appointment is booked, the patient receives a text message confirming the date and time of their appointment. For the efficacy trial, we inserted into the routine text an invitation to take part in contraception research by clicking on a hyperlink. Clicking on the hyperlink took women to the trial recruitment home page from where all procedures were the same as those described above.

## Statistical analysis

For the efficacy trial, the analysis focused on the effect size for the key clinical outcomes that became primary outcomes: use of a LARC method at 6 months and satisfaction with contraceptive method at 6 months.

The primary analysis is by modified intention to treat, basing analysis on those who complete at least one follow-up outcome questionnaire. For each outcome listed above, we present the percentage of participants if the outcome is binary (e.g. use of LARC) or ordinal (e.g. effectiveness of method, satisfaction with method) together with a 95% CI. These percentages and means are reported separately by intervention and standard care arm.

To formally assess differences between arms, we use logistic regression (for binary outcomes) or ordinal logistic regression (for ordinal outcomes), reporting adjusted odds ratios (ORs) with 95% CIs.

The primary outcome of LARC use at 6 months is analysed among women in need of contraception (not pregnant or currently trying to become pregnant) and the primary outcome of satisfaction with method is analysed among women who are using a method at 6 months. The primary outcome of LARC use at 6 months is analysed stratified by LARC use at baseline, leading to three intervention effects: (1) the effect in baseline LARC users, (2) the effect in baseline non-users and (3) the overall effect adjusted for baseline LARC use. Assuming that < 90% of baseline LARC users in the control arm are using a LARC method at 6 months, the primary effect measure is the overall adjusted intervention effect. If, conversely, > 90% of baseline LARC users in the control arm are using a LARC method at 6 months, the primary effect measure is the intervention effect in women not using a LARC method at baseline, because there would be little possibility of increasing LARC use through the intervention in baseline LARC users. Besides adjustment for baseline LARC use, analysis of both primary outcomes is also adjusted for satisfaction with method at baseline and setting. A further subgroup analysis is also presented for both primary outcomes to assess, based on testing an interaction term, whether or not the effect of the intervention varies by setting.

Primary comparisons for the primary outcomes between arms are based on multiple imputation, for which the primary outcomes at 6 months are imputed based on the outcomes at 3 months for those participants who completed the 3-month outcome questionnaire but failed to complete the questionnaire at 6 months. Imputation was conducted using the chained equations approach and implemented using the `mi impute` function in Stata; 20 imputed data sets were generated.

A post hoc decision was made to conduct a 'per-protocol' analysis for the primary outcomes based on a comparison of intervention arm participants who reported seeing the Contraception Choices website with all control arm participants.

### Costs of contraception and budget impact analysis

The primary analysis is a budget impact analysis of the website and contraception reporting the total costs to each payer [NHS (primary care vs. secondary care), local government, private and out of pocket]. This will be reported as the total cost of contraception and pregnancy outcomes for a range of different population sizes. The analysis conforms to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) good practice guidelines for budget impact analysis.<sup>30</sup>

Costs include the cost of contraception (NHS and out-of-pocket costs), including the cost of LARC, sexual health service use, sexual health-related primary and acute care use, and the cost of pregnancy-related outcomes. Resource use collected as part of the trial is costed based on published sources including Personal Social Services Research Unit (PSSRU) reference costs<sup>31</sup> and the *British National Formulary*.<sup>32</sup> Details for unit costs are reported in *Table 3*. For contraception, when there is more than one option, for example the different types of the combined pill, the lowest-cost option of (1) the option recommended by the NHS or, if not available, (2) the most commonly taken was used to determine the cost used. Out-of-pocket costs are costed at the same value as publicly financed costs except in the case of condoms, in which case it is assumed that three are given out by the NHS or other community sexual health services, but that people buy a pack of 24 if bought out of pocket. All costs are reported in 2016/17 Great British pounds.

At 6 months, participants were asked if they had become pregnant in the past 6 months and the outcome of the pregnancy. The cost of termination is costed as the weighted costs for all terminations in the NHS (£840 reference costs). The cost per miscarriage and cost per full-term pregnancy were taken from Public Health England<sup>33</sup> contraception return on investment analysis at £653 and £5735 per pregnancy, respectively.

The cost of the website includes ongoing maintenance costs and how these might be incurred by organisations that wish to use the website in the future. This cost is reported for a range of different population sizes.

In addition to the budget impact analysis of total cost for each payer, we report descriptive statistics for each cost type. We calculated the average total health-care cost of contraception per participant for the website compared with current practice at baseline and 6 months. The 95% CIs for each analysis are reported based on linear regression adjusting for baseline and site and bootstrapping with bias-corrected adjustment.

As there is limited information available on the number of free condoms that women obtain from the NHS every 3 months, we assumed cost containment and the minimum number per pack (three condoms). We have included a sensitivity analysis in which this number is increased to 12 every 3 months, the number available on a condom card, at a cost of £9.99 every 3 months.

TABLE 3 Cost of contraception-related resource use

Resource	Unit cost (for 3 months for medication) (£)	Reference
General practice	31.00	PSSRU <sup>31</sup>
Sexual health clinic	121.12	Reference costs <sup>34</sup>
Young persons' clinic (assume NHS band 5 nurse)	12.00	PSSRU <sup>31</sup>
Pharmacy	8.80	PSNC <sup>35</sup>
Gynaecology	140.93	Reference costs <sup>34</sup>
Combined or unknown pill [ethinylestradiol with norgestimate (Cilest)]	7.16	BNF <sup>32</sup>
Mini pill [desogestrel (Cerazette)]	2.75	BNF <sup>32</sup>
Contraceptive patch [ethinylestradiol with norelgestromin (EVRA)]	19.51	BNF <sup>32</sup>
Vaginal ring [ethinylestradiol with etonogestrel (NuvaRing)]	29.70	BNF <sup>32</sup>
Pack of condoms (24 pack)	11.99	Boots <sup>36</sup>
Condoms (three free per 3 months)	2.29	Boots <sup>36</sup>
Female condoms (pack of five)	5.99	Amazon <sup>37</sup>
Emergency contraception [ulipristal acetate (EllaOne)]	14.05	BNF <sup>32</sup>
Diaphragm	10.21	BNF <sup>32</sup>
Injectable contraception [medroxyprogesterone acetate (Provera)]	6.01	BNF <sup>32</sup>
Implant [etonogestrel (Nexplanon)]	83.43	BNF <sup>32</sup>
Intrauterine system [levonorgestrel (Mirena)]	83.43	BNF <sup>32</sup>
Intrauterine device: copper	8.95	BNF <sup>32</sup>
Vasectomy	829.57	Reference costs <sup>34</sup>
Female sterilisation	2416.00	Reference costs <sup>34</sup>

BNF, *British National Formulary*; PSNC, *Pharmaceutical Services Negotiating Committee*.

## Ethics issues

In describing the ethical issues to the Research Ethics Committee, we included the following points:

- We did not foresee major ethical issues or risks associated with asking individual participants or groups of women (focus group discussions) about access, acceptability and adherence to different methods of contraception, or the likely features of an IDI that might help them make better contraceptive choices. Nonetheless, all interviews and focus groups were facilitated in a sensitive manner by experienced researchers, setting out ground rules at the start for mutual respect and non-judgemental stances about lifestyle or behaviour choices.
- It is important to include women aged 15 years, as around one-fifth to one-third of women have had sexual intercourse before the age of 16 years and the intention was to help inform young women's first thoughts and choices about contraception. A substantial proportion of women attending community pharmacy and specialist contraceptive services, in particular, are aged 15 years.
- We assessed capacity to consent to the research by offering written study information and by answering any queries about the research. Young women wishing to discuss this with parents or others first were encouraged to do so. We did not require parental consent, as young women may be excluded from the research if parental consent was required.

The study was approved by London – Camden & King's Cross Research Ethics Committee and by the Health Research Authority, including substantial amendments (reference 17/LO/0112).





# Chapter 4 Trial results

## Recruitment

The first participant was randomised on 4 July 2017 and the last on 22 December 2017.

The first recruitment through the MPC online central booking service was on 31 October 2017 and the last on 22 December 2017.

Recruitment online was much faster than in the clinics. It took approximately 6 months to recruit 400 women from the clinic sites, as originally planned; we recruited 530 women via the online booking system in just over 7 weeks.

## Follow-up

The last follow-up survey was completed on 16 August 2018.

The Consolidated Standards of Reporting Trials (CONSORT) flow diagram (*Figure 2*) details the flow of participants through the trial.

In total, 927 women were randomised to the website ( $n = 464$ ) or to the control group ( $n = 463$ ), of whom 739 (80%) provided follow-up data at 6 months and 786 (86%) provided data at 3 and/or 6 months for analysis of primary outcomes with imputation.

Follow-up rates were similar across all sites (data not shown), except the British Pregnancy Advisory Service (BPAS), for which the follow-up rate was only 50%. Women often gave incorrect contact details that prevented follow-up.

The quality of the survey data collected was exceptionally high, with nearly 100% of women responding to the follow-up questionnaires providing the primary outcome data.

A total of 19 women (2%) withdrew from the trial: 11 from the intervention group and 7 from the control group. They did not offer reasons for withdrawing.

## Qualitative findings

Over four-fifths of participants in the intervention group provided free-text comments in the follow-up surveys at 3 and 6 months. All free-text comments were coded and analysed using thematic analysis. Comments about the website were overwhelmingly positive, with a few neutral comments from women who were already well informed. The only negative comments were from women with medical conditions, such as polycystic ovary syndrome, who did not find information specific to their condition.

The following themes and subthemes emerged.

### Information/website content

#### Evidenced-based and trustworthy information

*As a trainee GP myself I would definitely sign post people to this website in the future when discussing contraception.*




FIGURE 2 Consolidated Standards of Reporting Trials (CONSORT) flow diagram. Reproduced with permission from Stephenson *et al.*<sup>38</sup> This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<https://creativecommons.org/licenses/by/4.0/>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>). The figure includes minor additions and formatting changes to the original text.

### Increased knowledge and awareness about contraception

*I feel very well educated thanks to the website - I wish someone had explained about all the different choices years ago.*

### Honest information about pros and cons

*It's nice to get an overview of all contraception options out there, the pros and cons, so you can review them in your own time.*

### Tailored information

*This website ensures girls can get the best contraception for THEM and only them.*

### Informative after having a baby

*I have just had a baby, however, in the next few months I believe that I will be looking at contraception and it [website] will be useful.*

## Website improvement suggestions

*I wish it had more tips on dealing with difficult conversations that can happen or knowing your rights (like what to do if your GP won't allow you to have the method you want, or tries to convince you that one type is better because it's cheaper) [sic].*

### Design and format

#### Visual aesthetics

*The interface is easy to use and aesthetically pleasing.*

#### User-friendly

*I love the simplicity of the website. It's easy to find the method of contraception you're interested in. It's informative and it's very quick finding what you need.*

#### Easy to understand

*The language is clear and simple, which is very helpful when English is not your first language.*

#### Accessible at any time

*I like that I can research safe and comfortable with reliable information from my own home.*

### Health professional interaction

#### Women felt more empowered to speak to their health professionals

*It has made me feel more confident. Prior I didn't really have anyone to speak to about contraception and I didn't feel comfortable discussing it with my doctors so this bridged the gap.*

#### Aiding appointments

*[Using the website at home meant] more time to consider options without feeling pressure to pick something that might not be the best option.*

### Reported impacts of the Contraception Choices website

#### Changing or considering swapping to a new contraceptive method

*I think it's [the website] got me thinking more about which contraception I should use. I'm quite happy with my pill and currently not sexually active, but I do think I would like to switch to a LARC if I am in a relationship again.*

#### Changing behaviour due to having misperceptions addressed

*It's cleared up some of my doubts and things I worried about (probably unconsciously!) about hormonal contraception.*

## Reminders to act

*If anything the e-mails have been a helpful reminder to sort a more permanent solution for my contraception needs.*

## Discussing the website with others

*It's [the website] helped me be more open about contraception and discuss it with friends. It's become less of a taboo.*

## Health service barriers to accessing contraception

### Lack of appointments/long waiting times

*Long waiting times. GP did not offer the services to get implant fitted. Lack of sexual health clinics in my area means very long waiting times.*

### Lack of services offering long-acting contraception methods

*Very difficult to find an appointment to have an implant replaced due to GPs no longer offering this service. Spent 2 full days off work waiting in clinics but was not seen. Implant was 1 month out of date before I was able to book an appointment.*

*I wanted the coil but I found it difficult to find someone to fit it in London.*

## Being part of the study

*I feel I'm part of a community of (mainly) women who are talking about sexual health openly. I wish I had seen studies like this when I was younger and just beginning to be sexually active, as I wouldn't have felt as scared or alone as I did.*

## Quantitative findings

The baseline characteristics by study arm (Table 4) show that 419 women were recruited in clinics and 508 women were recruited via the MPC online booking system. Recruitment within clinics was highest for the MPC and lowest in BPAS.

TABLE 4 Baseline characteristics by study arm

Characteristic	Intervention (N = 464), % (n)	Control (N = 463), % (n)
Site of recruitment		
MPC	8.6 (40)	8.4 (39)
Clerkenwell	7.3 (34)	8.2 (38)
BPAS	4.5 (21)	4.8 (22)
Ashford	8.4 (39)	8.6 (40)
Green Light	6.9 (32)	7.1 (33)
Brook	8.8 (41)	8.6 (40)
Central booking	55.4 (257)	54.2 (251)

TABLE 4 Baseline characteristics by study arm (continued)

Characteristic	Intervention (N = 464), % (n)	Control (N = 463), % (n)
<b>Demographic factor</b>		
Age (years), median (IQR)	24 (21–27)	24 (21–27)
Ethnicity		
White	67.0 (306)	71.0 (326)
Mixed	11.6 (53)	10.5 (48)
Asian	10.3 (47)	8.1 (37)
Black	9.0 (41)	8.3 (38)
Other	2.2 (10)	2.2 (10)
First language		
English	80.8 (375)	84.2 (390)
Not English	19.2 (89)	15.8 (73)
Highest completed level of education		
Degree	51.3 (238)	49.9 (231)
Diploma in higher education	10.6 (49)	9.7 (45)
A level/AS level	21.3 (99)	23.5 (109)
O level/GCSE	9.7 (45)	7.8 (36)
Other	5.4 (25)	5.8 (27)
None	1.7 (8)	3.2 (15)
<b>Contraception factor</b>		
Need for contraception		
No: pregnant	9.7 (45)	10.6 (49)
No: trying for baby	0.2 (1)	0.2 (1)
Yes: neither	90.1 (418)	89.2 (413)
Method used, if needed, ordered by efficacy		
None	17.7 (74)	18.6 (77)
Unclear	0.2 (1)	0.5 (2)
Withdrawal/natural	0 (0)	1.2 (5)
Condom/diaphragm	10.5 (44)	11.1 (46)
Pill/patch/ring	42.6 (178)	39.0 (161)
LARC/sterilisation	29.0 (121)	29.5 (122)
Satisfaction with method, if using a method		
Very dissatisfied	4.3 (15)	3.3 (11)
Dissatisfied	11.6 (40)	12.2 (41)
Neutral	16.2 (56)	17.2 (58)
Satisfied	36.4 (126)	32.6 (110)
Very satisfied	31.5 (109)	34.7 (117)
A level, Advanced level; AS level, Advanced subsidiary level; GCSE, General Certificate of Secondary Education; IQR, interquartile range; O level, Ordinary level.		

Just over two-thirds of participants were from white ethnic groups, half were educated to degree level and four-fifths reported English as their first language.

Ten per cent were pregnant, with the remaining 90% indicating a current need for contraception to avoid unintended pregnancy. The most common method was the pill, followed by LARC methods. Around two-thirds of women were satisfied with their current method at baseline.

Of the 364 intervention participants with 6-month follow-up data, 309 (85%) reported seeing the Contraception Choices website. Of those, 97% found it helpful or very helpful for 'getting useful information about contraception' and 87% responded that it was helpful or very helpful for 'finding a method of contraception that is right for you'.

**Primary outcomes**

There was no statistically significant difference between intervention and control groups in the proportion of women using LARC at 6 months [30.4% intervention vs. 31.0% control, adjusted OR after imputation 0.87 (95% CI 0.60 to 1.27)], nor in level of satisfaction with contraceptive method [proportion being 'satisfied' or 'very satisfied', 82.6% intervention vs. 82.1% control, adjusted ordinal OR 0.93 (95% CI 0.69 to 1.26)] based on the five ordered responses (Table 5).

TABLE 5 Comparison of outcomes between study arms

Outcome measure	Intervention, % (n)	Control, % (n)	Intervention vs. control, p-value, OR (95% CI)	p-value, adjusted OR (95% CI)
<b>Primary outcomes</b>				
LARC method in use at 6 months, overall (N = 713) <sup>a</sup>	30.4 (106)	31.0 (113)	p = 0.88 0.97 (0.71 to 1.35)	p = 0.62 0.91 (0.61 to 1.33)
After imputation			p = 0.74 0.95 (0.69 to 1.30)	p = 0.48 0.87 (0.60 to 1.28)
If using LARC at baseline (N = 201)	58.8 (57)	70.2 (73)	p = 0.08 0.59 (0.32 to 1.06)	p = 0.013 0.41 (0.21 to 0.83)
After imputation			p = 0.12 0.63 (0.35 to 1.12)	p = 0.024 0.46 (0.23 to 0.90)
If not using LARC at baseline (N = 512)	19.4 (49)	15.4 (40)	p = 0.19 1.37 (0.86 to 2.19)	p = 0.27 1.32 (0.81 to 2.15)
After imputation			p = 0.40 1.22 (0.77 to 1.92)	p = 0.49 1.18 (0.74 to 1.90)
Satisfaction with method used at 6 months, (N = 624) <sup>b</sup>				
Very dissatisfied	1.9 (6)	1.6 (5)		
Dissatisfied	4.2 (13)	5.8 (18)	p = 0.52 0.91 (0.68 to 1.22)	p = 0.65 0.93 (0.69 to 1.26)
Neutral	11.3 (35)	10.5 (33)		
Satisfied	39.9 (124)	35.5 (111)		
Very satisfied	42.8 (133)	46.7 (146)		
After imputation			p = 0.54 0.91 (0.68 to 1.22)	p = 0.62 0.93 (0.69 to 1.25)

TABLE 5 Comparison of outcomes between study arms (continued)

Outcome measure	Intervention, % (n)	Control, % (n)	Intervention vs. control, p-value, OR (95% CI)	p-value, adjusted OR (95% CI)
<b>Secondary outcomes</b>				
Effectiveness of contraceptive method at 6 months (N = 713) <sup>a</sup>				
None	10.9 (38)	14.0 (51)		
Withdrawal/natural	1.7 (6)	1.4 (5)	p = 0.63 1.07 (0.82 to 1.40)	p = 0.33 1.15 (0.87 to 1.52)
Condom/diaphragm	12.6 (44)	12.1 (44)		
Pill/patch/ring	44.4 (155)	41.5 (151)		
LARC/sterilisation	30.4 (106)	31.0 (113)		
Change in method from baseline to 6 months (N = 651) <sup>c</sup>				
Change to more effective	23.8 (76)	20.5 (68)		
Change to similarly effective	11.3 (36)	12.7 (42)	N/A	N/A
No change	46.3 (148)	51.1 (169)		
Change to less effective	18.8 (60)	15.7 (52)		
Pregnancy by 6 months (N = 670) <sup>d</sup>	3.3 (11)	4.1 (14)	p = 0.66 0.86 (0.43 to 1.69)	p = 0.76 0.90 (0.45 to 1.79)
STI diagnosis reported at 3 or 6 months (N = 624) <sup>e</sup>	5.3 (16)	4.7 (15)	p = 0.76 1.12 (0.55 to 2.31)	p = 0.72 1.14 (0.55 to 2.36)
N/A, not applicable; STI, sexually transmitted infection.				
a Analysis restricted to not pregnant or trying for baby at 6 months.				
b Analysis restricted to using a method at 6 months.				
c Analysis restricted to not pregnant or trying for baby at baseline or 6 months; clear reporting of method at both time points.				
d Analysis restricted to not pregnant or trying for baby at baseline.				
e Analysis restricted to completed 3- and 6-month questionnaire items.				

### Secondary outcomes

There was no difference between groups in the proportion of women who were pregnant at 6 months, or the proportion with a diagnosed sexually transmitted infection at 3 or 6 months.

Around half of the participants in each group changed their method of contraception between baseline and 6 months; the most common change was to a more effective method (24% intervention group, 21% control), but 19% in the intervention group and 16% in the control group changed to a less effective method.

The proportion of women in the intervention group who confirmed that they had seen the Contraception Choices website was 84.9%, whereas the proportion in the control group was < 7%, indicating good recognition in the intervention group and little contamination in the control group.

Post hoc per-protocol analysis of the primary outcomes was not appreciably different from the modified intention-to-treat analysis (Table 6).

TABLE 6 Post hoc per-protocol analysis of primary outcomes

Outcome measure	Intervention (seen website), % (n)	Control (all), % (n)	Intervention vs. control, <i>p</i> -value, OR (95% CI)	<i>p</i> -value, adjusted OR (95% CI)
LARC method in use at 6 months (N = 660) <sup>a</sup>	31.4 (93)	31.0 (113)	<i>p</i> = 0.86 1.03 (0.74 to 1.44)	<i>p</i> = 0.98 0.99 (0.66 to 1.49)
Satisfaction with method used at 6 months (N = 578) <sup>b</sup>				
Very dissatisfied	1.1 (3)	1.6 (5)		
Dissatisfied	4.2 (11)	5.8 (18)	<i>p</i> = 0.87 0.97 (0.72 to 1.33)	<i>p</i> = 0.95 1.01 (0.74 to 1.39)
Neutral	10.9 (29)	10.5 (33)		
Satisfied	39.3 (104)	35.5 (111)		
Very satisfied	44.5 (118)	46.7 (146)		

a Analysis restricted to not pregnant or trying for baby at 6 months.

b Analysis restricted to using a method at 6 months.

Reproduced with permission from Stephenson *et al.*<sup>38</sup> This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<https://creativecommons.org/licenses/by/4.0/>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>). The table includes minor additions and formatting changes to the original text.

## Budget impact analysis

The average cost of publicly funded contraception in the Contraception Choices website group over 6 months was £231 [standard error (SE) £9.90; *n* = 336], and it was £230 (SE £9.80; *n* = 346) in the control group. The average cost of pregnancy in the Contraception Choices group was £169 (SE £49.40; *n* = 364), and it was £84 (SE £31.30; *n* = 372) in the control group. The higher cost of pregnancy in the Contraception Choices group is not due to more pregnancies (see Table 8), but the fact that, among women who did get pregnant in the Contraception Choices group, and who were not trying for a baby at baseline, there were fewer terminations [*n* = 4 (1.0%) vs. *n* = 6 (1.4%)], although the numbers are very small and hence for explanatory purposes only. The average out-of-pocket contraception costs over 6 months were £53 (SE £5.60; *n* = 336) for the Contraception Choices group and £42 (SE £4.90; *n* = 346) for the intervention group.

Based on bias-corrected bootstrapped CIs (1000 iterations) and controlling for baseline cost and recruitment site, there was no statistically significant difference between the two groups in publicly funded contraception costs excluding pregnancy (£3.67, 95% CI -£18.17 to £28.56) or including pregnancy (£73.65, 95% CI -£46.38 to £192.40) or in private out-of-pocket costs (£11.19, 95% CI -£2.84 to £26.72). In the sensitivity analysis, assuming a higher cost every 3 months for free condoms from the NHS, the difference between the two groups for publicly funded contraception costs remains similar (£4.06, 95% CI - £28.87 to £17.87).

Table 7 reports the results of the budget impact assessment by providers. This is calculated as the average cost per woman for each provider in a given population, assuming that the population recruited to the trial is broadly representative of the wider population of women accessing contraception. The total cost was also extrapolated for the 5,128,093 women aged 15–30 years in England in 2017<sup>39</sup> and for an average local authority population of 14,000 women aged between 15 and 30 years. Table 8 reports the results by recruiting site. Values are greater in Table 8 as they reflect the total cost per woman in the study for all contraception use over 6 months (excluding pregnancy and out-of-pocket costs). For example, of the women recruited through a general practice, 11% also attended a sexual health clinic.



TABLE 7 Budget impact assessment reporting average cost per woman over 6 months

Provider	Contraception Choices, mean cost (£) per woman	Control, mean cost (£) per woman	Cost (£) difference (population n = 5,128,093)	Cost (£) difference (population n = 14,000)
General practice	13.18	14.36	-6,051,150	-16,520
Sexual health service	153.57	159.78	-31,845,458	-86,940
Acute health care	0.76	2.22	-7,487,016	-20,440
Acute health care, including pregnancy costs	160.22	93.05	344,454,007	940,380
Pharmacy costs	0.86	0.75	564,090	1540
Young persons' clinic	0.09	0.29	-1,025,619	-2800

TABLE 8 Average cost per woman (excluding pregnancy) and cost difference between Contraception Choices and control by recruiting site

Recruiting service	Contraception Choices cost (£)	Control cost (£)	Difference per woman (£)
MPC	277.00	282.61	-5.61
General practice	103.94	192.31	-88.37
Abortion service	145.25	143.09	2.16
Maternity service	13.65	35.30	-21.65
Pharmacy	191.91	147.53	44.38
Brook sexual health service	233.43	124.85	108.59

The 6-month cost of hosting the website is £3021. For the MPC (central booking plus the MPC), which recruited 587 patients in total, this would be equivalent to £5.15 per patient, similar to the cost savings its patients achieved as part of the study (see *Table 8*). For a local authority of 14,000 patients, this works out to approximately £0.21 per patient and across the whole of England it starts to approach £0 per woman.

## Health-related quality of life

Initial qualitative work associated with developing the questionnaires identified that women did not find a health-related quality-of-life measure (the EuroQol-5 Dimensions) or a condition-specific measure (Sexual Quality of Life) appropriate for the study. As a result, we did not include either of these measures as an outcome. However, the initial work was completed as a systematic review of the quality-of-life measures for contraception and an MSc thesis [see [www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/137909/#/) (accessed January 2020)].



## Chapter 5 Discussion

We describe here the process and outcomes of designing and evaluating Contraception Choices, an interactive website to aid informed choice of contraception. The evidence base for the website came from extensive systematic review of published literature, review of social media (YouTube), empirical qualitative research with young women and expert opinion. The evaluation method was unusually rigorous for a website; according to recent NICE guidance, a randomised trial is the standard reserved for those digital health technologies that aim to prevent and manage disease.<sup>40</sup>

At the outset, we did not expect to complete an efficacy (Phase III) trial of the website, but immediate demand for Contraception Choices from service providers, who could signpost patients to it through their own clinic websites, prompted the transition from a feasibility to an efficacy trial. Overall, the study procedures worked well and were highly efficient: the total project expenditure, or cost to the funder, for intervention design and evaluation combined was < £754 per participant. Leaving aside delays in Phase I due to the lengthy process of obtaining all research permissions, the trial processes worked well: the follow-up rate was good, with 86% of participants providing primary outcome data at 6 months. Even recruitment in clinics was completed within the anticipated 6 months, but recruiting online (via the MPC online booking system) was much more efficient, being both faster and without additional cost. Just over half of all participants were recruited in this way in < 8 weeks.

Our study underscores other evidence that online trials are an efficient method of conducting clinical trials of low-risk interventions, and that such methods are acceptable to participants.<sup>18</sup> Other research suggests that online recruitment methods in trials of online interventions can improve the validity of the findings.<sup>19</sup> In our study, women recruited online had a different experience of being in the trial to women recruited while attending a clinic or pharmacy, but there were no statistically significant differences in outcomes by method of recruitment (data not shown).

Given the strikingly positive feedback about the website, from women and health-care providers, the high level of intervention reach (over four-fifths viewed the website) and low 'contamination' in the control group (only 7% of the control group reported seeing the website), the lack of difference in primary outcomes between groups was disappointing. The free-text comments appeared to affirm the purpose of the website and, arguably, the theoretical basis that might lead to efficacy, but this was not observed in quantitative terms. Possible reasons relate to the many influences on contraceptive use beyond a woman's control, as evidenced by our systematic review and reported barriers to accessing services to obtain a desired method, due to difficulties in getting appointments, long waiting times and a lack of services that can fit LARC methods. Other possible reasons include a longer follow-up period needed for intentions stimulated by the website to translate into action; measurement reactivity (i.e. the possible impact of asking the control group about their contraception use); the limitations of a broad outcome measure such as 'satisfaction with method'; and the possibility that both the intervention group and the control group were receiving high-quality clinical care, so that the website could not show an additional effect. With hindsight, we might have seen statistically significant differences between groups had we included intermediate outcomes, such as 'feeling better informed about choice of methods' or 'feeling confident about discussing different contraceptive methods with a health professional', but, ultimately, we were interested in increasing the number of women using an effective contraceptive method through providing information on all available options, their advantages and disadvantages, and dispelling common myths. The finding, for the subset of women using LARC at baseline, that LARC use at 6 months was lower in the intervention group than in the control group raises the possibility that women had gained information from the website that led them to choose an alternative method that suited them better than LARC. Although the data do not allow us to draw firm conclusions about this, we know that LARC methods, despite being the most effective at preventing pregnancy, do not suit all women and it would be unhelpful to assume otherwise. In general, though, there was no statistically significant difference between groups in the proportion of women who changed to a more or less effective method.

Our systematic review of quality-of-life measures did not identify a suitable measure of quality of life for women using contraception that would allow us to conduct a cost per quality-adjusted life-year (QALY) analysis. However, NICE public health methods guidance recognises that cost per QALY may not always be the most suitable analysis for an economic evaluation in public health interventions. Cost-consequences analysis, reporting costs alongside effectiveness measures, is sometimes recommended as a more suitable economic evaluation method.

If the aim of a future trial is to inform NICE guidance, then new NICE digital health intervention guidance may be the most relevant. The current draft guidance suggests both a cost-per-QALY analysis and a budget impact analysis. More work is therefore required on developing a suitable preference-based measure in contraception. If local decision-makers are the key audience, then budget impact analysis or return on investment, in addition to evidence on clinical effectiveness and safety, may be sufficient, as local decision-makers are primarily interested in direct financial implications for their services.

Given the increase in sample size and the decision to examine efficacy, we chose, in addition, to look at statistical significance in costs. There was no statistically significant difference between the two groups in costs. Pregnancy costs were higher in the intervention groups (although not statistically significantly so) because more pregnancies were carried to full term and there were fewer terminations in the Contraception Choices group, rather than more pregnancies in total.

The advantage of the Contraception Choices website as an intervention to provide women with balanced information to support their choice of contraception method is that the intervention can be rolled out to a large number of women with no additional cost, as it includes only the fixed cost of website maintenance and hosting. Consequently, as more women access the website the cost per woman approaches zero.

In terms of implementing the website in NHS services, the method of directing patients to the Contraception Choices website via a text message to confirm a clinic appointment booked online seems a promising way forward. It enables large numbers of women to have access to the website at the time of planning a contraceptive consultation when they are likely to benefit from a more informed discussion with a doctor or nurse. It is easy to imagine a woman bringing to her appointment three contraception options generated by 'What's Right for Me?' on her mobile phone and seeing the website open on the health professional's computer screen in the clinic. For this study, we did not aim to assess such a development in clinical practice, but we hypothesise that it could lead to a more satisfying consultation for both individuals, with potentially better clinical or service outcomes.

## Chapter 6 Conclusions/recommendations

The Contraception Choices website was popular among young women for its design, presentation of trustworthy information and guidance in choosing a method tailored to individual preferences. It is currently promoted via a link on the NHS website, which receives around 11 million visits per year [URL: [www.nhs.uk/conditions/contraception/which-method-suits-me/](http://www.nhs.uk/conditions/contraception/which-method-suits-me/) (accessed January 2020)]. However, it was not associated with any statistically significant difference in use of LARC or satisfaction with contraceptive method at 6 months. Our systematic reviews confirmed multiple factors affecting women's choice and use of contraception that go beyond informed choice, including the influence of partners, friends, family, school, religion, wider culture and health services.

The availability of the website on the internet offers many possibilities for further use and evaluation. In our systematic review, we found remarkable consistency across the globe in factors influencing contraception choice, uptake and use. With appropriate adaptations, Contraception Choices may be of benefit to populations in different settings (e.g. schools, non-clinic populations) or different countries; we are currently exploring its utility in Botswana, a country with advanced e-health capacity and high human immunodeficiency virus prevalence.

The lack of effect on clinical outcomes in this trial, despite highly positive feedback from participants, highlights a gap between improving delivery of information and impact on contraceptive use. We hypothesise that this gap can be narrowed by shared reference to the website between patients and health-care professionals during contraception consultations. Contraception providers are keen to promote the website. Future research could examine the impact of the website in different settings (e.g. in schools) or different countries. Specifically, we recommend research to determine whether or not use of the website during contraceptive consultations improves the quality or efficiency of consultation for both patients and health-care providers.



# Acknowledgements

**W**e would like to thank the following individuals and groups:

Study co-applicants Greta Rait, Jill Shawe, Jonathan Poon, Patricia Lohr and Chris Wilkinson for facilitating recruitment in clinics.

Caitlin Bawn for screening citations and selecting papers for the systematic review of IDI for Contraception Choices.

Lisa Walton for drafting clinical content of the Contraception Choices website.

Kirsty Bennett and Laura Harrington for conducting qualitative evaluation of trial procedures and women's views of the website.

Alice Howe for systematic review of health-related quality-of-life measures for women using contraception.

Carla Logon-Bishop for formatting the report.

PRIMENT Clinical Trials Unit and Sealed Envelope Ltd (London, UK) for supporting the conduct of the randomised trial.

Gene Feder (chairperson) and members of the Trial Steering Committee.

## Contributions of authors

**Judith Stephenson** (<https://orcid.org/0000-0002-8852-0881>) led on the trial, contributed to the design, development and/or evaluation of the Contraception Choices website, commented on successive drafts of the paper and approved the final version.

**Julia V Bailey** (<https://orcid.org/0000-0002-5001-0122>) led on the website development, contributed to the design, development and/or evaluation of the Contraception Choices website, commented on successive drafts of the paper and approved the final version.

**Ann Blandford** (<https://orcid.org/0000-0002-3198-7122>) led on the expert input to the website design, commented on successive drafts of the paper and approved the final version.

**Nataliya Brima** (<https://orcid.org/0000-0002-6930-5166>) contributed to the randomisation list, database testing and data analysis plan, contributed to the design, development and/or evaluation of the Contraception Choices website, commented on successive drafts of the paper and approved the final version.

**Andrew Copas** (<https://orcid.org/0000-0001-8968-5963>) led on the trial design and analysis, contributed to the design, development and/or evaluation of the Contraception Choices website, commented on successive drafts of the paper and approved the final version.

**Preethy D'Souza** (<https://orcid.org/0000-0003-3604-2280>) conducted the systematic literature reviews, contributed to the design, development and/or evaluation of the Contraception Choices website, commented on successive drafts of the paper and approved the final version.

## ACKNOWLEDGEMENTS

**Anasztazia Gubijev** (<https://orcid.org/0000-0003-4317-5866>) conducted the interviews and focus groups, reviewed YouTube videos, led the in-person trial recruitment, co-ordinated the trial follow-up, analysed the qualitative data, contributed to analysis of the trial data, contributed to the design, development and/or evaluation of the Contraception Choices website, commented on successive drafts of the paper and approved the final version.

**Rachael Hunter** (<https://orcid.org/0000-0002-7447-8934>) contributed to design of the online trial, contributed to the design, development and/or evaluation of the Contraception Choices website, commented on successive drafts of the paper and approved the final version.

**Jill Shawe** (<https://orcid.org/0000-0002-2766-7302>) co-ordinated the maternity recruitment, analysed the qualitative data, contributed to the design, development and/or evaluation of the Contraception Choices website, commented on successive drafts of the paper and approved the final version.

**Greta Rait** (<https://orcid.org/0000-0002-7216-7294>) led primary care recruitment, contributed to trial design, contributed to the design, development and/or evaluation of the Contraception Choices website, commented on successive drafts of the paper and approved the final version.

**Sandy Oliver** (<https://orcid.org/0000-0001-9571-269X>) led on the systematic reviews and meta-synthesis of literature, contributed to the design, development and/or evaluation of the Contraception Choices website, commented on successive drafts of the paper and approved the final version.

## Publication

Stephenson J, Bailey JV, Gubijev A, d'Souza P, Oliver S, Blandford A, *et al.* An interactive website for informed contraception choice: randomised evaluation of Contraception Choices. *Digital Health* 2020;**6**:2055207620936435.

## Data-sharing statement

All available data can be obtained from the corresponding author.



## References

1. GOV.UK. *Abortion Statistics, England Wales, 2017*. London: Department of Health and Social Care; 2017.
2. Armstrong N, Donaldson C. *The Economics of Sexual Health*. London: Family Planning Association; 2005.
3. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, Secura GM. Effectiveness of long-acting reversible contraception. *N Engl J Med* 2012;**366**:1998–2007. <https://doi.org/10.1056/NEJMoa1110855>
4. National Collaborating Centre for Women's and Children's Health. *Long-acting Reversible Contraception: The Effective and Appropriate Use of Long-Acting Reversible Contraception*. 2005. URL: [www.ncbi.nlm.nih.gov/books/NBK51051/](http://www.ncbi.nlm.nih.gov/books/NBK51051/) (accessed 18 June 2019).
5. NHS Digital. *NHS Contraceptive Services, England - 2012–13, Community Contraceptive Clinics*. 2013. URL: <https://digital.nhs.uk/data-and-information/publications/statistical/nhs-contraceptive-services/nhs-contraceptive-services-england-2012-13-community-contraceptive-clinics> (accessed 18 June 2019).
6. French RS, Geary R, Jones K, Glasier A, Mercer CH, Datta J, et al. Where do women and men in Britain obtain contraception? Findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). *BMJ Sex Reprod Health* 2018;**44**:16–26. <https://doi.org/10.1136/jfprhc-2017-101728>
7. Lopez LM, Grey TW, Chen M, Tolley EE, Stockton LL. Theory-based interventions for contraception. *Cochrane Database Syst Rev* 2016;**11**:CD007249. <https://doi.org/10.1002/14651858.CD007249.pub5>
8. Halpern V, Lopez LM, Grimes DA, Stockton LL, Gallo MF. Strategies to improve adherence and acceptability of hormonal methods of contraception. *Cochrane Database Syst Rev* 2013;**10**:CD004317. <https://doi.org/10.1002/14651858.CD004317.pub4>
9. Arrowsmith ME, Aicken CR, Saxena S, Majeed A. Strategies for improving the acceptability and acceptance of the copper intrauterine device. *Cochrane Database Syst Rev* 2012;**3**:CD008896. <https://doi.org/10.1002/14651858.CD008896.pub2>
10. Matthews D. *Internet Access Quarterly Update: Q4 2013*. 2014. URL: [www.ons.gov.uk/peoplepopulationandcommunity/householdcharacteristics/homeinternetandsocialmediausage/bulletins/internetaccessquarterlyupdate/2014-02-19](http://www.ons.gov.uk/peoplepopulationandcommunity/householdcharacteristics/homeinternetandsocialmediausage/bulletins/internetaccessquarterlyupdate/2014-02-19) (accessed 18 June 2019).
11. McCarthy O, Carswell K, Murray E, Free C, Stevenson F, Bailey JV. What young people want from a sexual health website: design and development of Sexunzipped. *J Med Internet Res* 2012;**14**:e127. <https://doi.org/10.2196/jmir.2116>
12. Bailey JV, Murray E, Rait G, Mercer CH, Morris RW, Peacock R, et al. Interactive computer-based interventions for sexual health promotion. *Cochrane Database Syst Rev* 2010;**9**:CD006483. <https://doi.org/10.1002/14651858.CD006483.pub2>
13. Garbers S, Meserve A, Kottke M, Hatcher R, Ventura A, Chiasson MA. Randomized controlled trial of a computer-based module to improve contraceptive method choice. *Contraception* 2012;**86**:383–90. <https://doi.org/10.1016/j.contraception.2012.01.013>
14. Garbers S, Meserve A, Kottke M, Hatcher R, Chiasson MA. Tailored health messaging improves contraceptive continuation and adherence: results from a randomized controlled trial. *Contraception* 2012;**86**:536–42. <https://doi.org/10.1016/j.contraception.2012.02.005>

## REFERENCES

15. Schwarz EB, Burch EJ, Parisi SM, Tebb KP, Grossman D, Mehrotra A, Gonzales R. Computer-assisted provision of hormonal contraception in acute care settings. *Contraception* 2013;**87**:242–50. <https://doi.org/10.1016/j.contraception.2012.07.003>
16. Schwarz EB, Gerbert B, Gonzales R. Computer-assisted provision of emergency contraception a randomized controlled trial. *J Gen Intern Med* 2008;**23**:794–9. <https://doi.org/10.1007/s11606-008-0609-x>
17. Wilson A, Nirantharakumar K, Truchanowicz EG, Surenthirakumaran R, MacArthur C, Coomarasamy A. Motivational interviews to improve contraceptive use in populations at high risk of unintended pregnancy: a systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol* 2015;**191**:72–9. <https://doi.org/10.1016/j.ejogrb.2015.05.010>
18. Pazol K, Zapata LB, Tregear SJ, Mautone-Smith N, Gavin LE. Impact of contraceptive education on contraceptive knowledge and decision making: a systematic review. *Am J Prev Med* 2015;**49**(Suppl. 2):46–56. <https://doi.org/10.1016/j.amepre.2015.03.031>
19. Oringanje C, Meremikwu MM, Eko H, Esu E, Meremikwu A, Ehiri JE. Interventions for preventing unintended pregnancies among adolescents. *Cochrane Database Syst Rev* 2009;**4**:CD005215. <https://doi.org/10.1002/14651858.CD005215.pub2>
20. Lopez LM, Grey TW, Chen M, Hiller JE. Strategies for improving postpartum contraceptive use: evidence from non-randomized studies. *Cochrane Database Syst Rev* 2014;**11**:CD011298. <https://doi.org/10.1002/14651858.CD011298.pub2>
21. Jepson RG, Hewison J, Thompson AG, Weller D. How should we measure informed choice? The case of cancer screening. *J Med Ethics* 2005;**31**:192–6. <https://doi.org/10.1136/jme.2003.005793>
22. Dehlendorf C, Levy K, Kelley A, Grumbach K, Steinauer J. Women's preferences for contraceptive counseling and decision making. *Contraception* 2013;**88**:250–6. <https://doi.org/10.1016/j.contraception.2012.10.012>
23. Barnet B, Liu J, DeVoe M, Duggan AK, Gold MA, Pecukonis E. Motivational intervention to reduce rapid subsequent births to adolescent mothers: a community-based randomized trial. *Ann Fam Med* 2009;**7**:436–45. <https://doi.org/10.1370/afm.1014>
24. Barnet B, Rapp T, DeVoe M, Mullins CD. Cost-effectiveness of a motivational intervention to reduce rapid repeated childbearing in high-risk adolescent mothers: a rebirth of economic and policy considerations. *Arch Pediatr Adolesc Med* 2010;**164**:370–6. <https://doi.org/10.1001/archpediatrics.2010.16>
25. Sridhar A, Chen A, Forbes ER, Glik D. Mobile application for information on reversible contraception: a randomized controlled trial. *Am J Obstet Gynecol* 2015;**212**:774.e1–7. <https://doi.org/10.1016/j.ajog.2015.01.011>
26. Antonishak J, Kaye K, Swiader L. Impact of an online birth control support network on unintended pregnancy. *Soc Mar Q* 2015;**21**:23–36. <https://doi.org/10.1177/1524500414566698>
27. Faculty of Sexual and Reproductive Healthcare. *Service Standards for Sexual and Reproductive Healthcare*. London: Faculty of Sexual and Reproductive Healthcare; 2016.
28. Guillebaud J, MacGregor A. *Contraception: Your Questions Answered*. 7th edn. Amsterdam: Elsevier; 2017.
29. Bailey JV, Pavlou M, Copas A, McCarthy O, Carswell K, Rait G, et al. The Sexunzipped trial: optimizing the design of online randomized controlled trials. *J Med Internet Res* 2013;**15**:e278. <https://doi.org/10.2196/jmir.2668>

30. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, *et al.* Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices – budget impact analysis. *Value Health* 2007;**10**:336–47. <https://doi.org/10.1111/j.1524-4733.2007.00187.x>
31. Curtis L, Burns A. *Unit Costs of Health and Social Care 2018*. Canterbury: PSSRU, University of Kent; 2018.
32. Joint Formulary Committee. *British National Formulary (online)*. London: BMJ Group and Pharmaceutical Press. URL: [www.medicinescomplete.com](http://www.medicinescomplete.com) (accessed June 2020).
33. Public Health England. *Contraception: Economic Analysis Estimation of the Return on Investment (ROI) for Publicly Funded Contraception in England*. London: Public Health England; 2018.
34. NHS Improvement. *Reference Costs 2017–2018*. URL: <https://improvement.nhs.uk/resources/reference-costs/> (accessed June 2020).
35. Pharmaceutical Services Negotiating Committee. *What Does the Patient Pay?* 2018. URL: <https://psnc.org.uk/dispensing-supply/receiving-a-prescription/patient-charges/> (accessed 20 December 2018).
36. Boots: Boots Company Plc. *Condoms and Sexual Health*. 2018. URL: [www.boots.com/health-pharmacy/condoms-sexual-health](http://www.boots.com/health-pharmacy/condoms-sexual-health) (accessed 10 October 2018).
37. Amazon. *Amazon.com Inc.* URL: <https://amazon.co.uk> (accessed June 2020).
38. Stephenson J, Bailey JV, Gubijev A, d'Souza P, Oliver S, Blandford A, *et al.* An interactive website for informed contraception choice: randomised evaluation of *Contraception Choices*. *Digital Health* 2020;**6**:2055207620936435. <https://doi.org/10.1177/2055207620936435>
39. Office for National Statistics. *Dataset: Estimates of the Population for the UK, England and Wales, Scotland and Northern Ireland*. Newport: Office for National Statistics; 2018.
40. National Institute for Health and Care Excellence. *Evidence Standards Framework for Digital Health Technologies*. London: National Institute for Health and Care Excellence; 2018.





EME  
HS&DR  
**HTA**  
PGfAR  
PHR

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care*

***Published by the NIHR Journals Library***